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ABSTRACT OF THE DISSERTATION
Understanding the evolution of HIV-1 Env through computational analysis and
visualization of long-read amplicon sequences
by
Kemal Eren
Doctor of Philosophy in Bioinformatics and Systems Biology
University of California, San Diego, 2017
Professor Joel Okrent Wertheim, Chair
Professor Siavash Mir Arabbaygi, Co-Chair
Single-molecule long-read sequencing technology recently reached accuracies
useful for studying diverse viral genes and genomes. Challenging error profiles, however,
hinder the interpretability of long-read sequencing datasets. Here we develop compu-
tational tools for processing such datasets and for visualizing rapidly evolving viral
populations.
Our primary biological focus is the HIV-1 envelope protein, which is the only
target of neutralizing antibodies. An effective HIV-1 vaccine would be a powerful weapon
xiv
against the current global epidemic, but progress has been slow because Env is a difficult
target. Nevertheless, some hosts develop broadly neutralizing antibodies (bNAbs), which
could be protective if they could be elicited by vaccination. Env and bNAb lineages
co-evolve, so understanding the Env populations and evolutionary dynamics will likely be
critical for understanding how to elicit the desired immune response. Tools developed in
this dissertation allow, for the first time, accurate processing of full-length sequencing of
HIV-1 env populations. Computational challenges in analyzing these sequences include
the length of the gene (2.6kb) and the prevalence of indel sequencing errors and extensive
biological indel variation which render traditional approaches inaccurate.
FLEA is a pipeline for processing circular consensus sequences and providing
biological insights into the evolution of env. It performs sequence cleaning, infers
high-quality consensus sequences, and performs analyses including codon alignment,
phylogenetic tree inference, ancestor reconstruction, and selection inference. The FLEA
pipeline supports multiple cluster and high-performance computing environments. A
client-side web application provides interactive visualizations, including a tree viewer,
MSA browser, and three-dimensional structure viewer.
RIFRAF is a novel multi-objective sequence consensus algorithm. It uses per-base
quality scores and uses a reference sequence for frame correction. RIFRAF consistently
finds consensus sequences that are more accurate and in-frame than those from other
methods, even with few reads and a distant reference. It is also uniquely capable of
keeping true indels while removing spurious ones.
These tools have been used to study donors from the Protocol C primary infection
cohort, resulting in two high-profile journal articles and another in preparation. They have
also been used to analyze data from a phase-I clinical trial of an anti-Env monoclonal
antibody therapy, published in Nature Medicine. This dissertation reviews those articles,
focusing on the results obtained with these tools.
xv
Chapter 1
Background and motivation
1.1 HIV-1
Human immunodeficiency virus (HIV) is a retrovirus that infects CD4-positive
cells, such as T-cells and macrophages. After an initial viral load spike, the infection
becomes asymptomatic for a period of months to years. Without treatment, this stage
usually ends within ten years, causing acquired immunodeficiency syndrome (AIDS) due
to the depletion of CD4-positive T cells. The compromised immune system is vulnerable
to opportunistic infections or cancers, which are almost always fatal. A worldwide HIV
pandemic has been raging for decades, causing millions of deaths.
HIV descends from Simian Immunodeficiency Virus (SIV), which crossed the
species barrier into humans from primates [105]. SIV is an old virus, estimated to have
been circulating in simian populations for more than 32,000 years, during which time it
may have successfully crossed into humans multiple times [156]. However, the ancestor
of the current pandemic crossed into humans relatively recently. HIV-1, which is the
most prevalent type, is related to SIV in chimpanzees and gorillas. HIV-1 group M,
which is responsible for the global pandemic, came from SIVcpz (a strain of HIV that
1
2infects chimpanzees), probably in the late 19th or early 20th century in Cameroon or the
Democratic Republic of the Congo, as a result of human contact with chimpanzee blood
while harvesting bushmeat [143]. Factors that may have contributed to its spread include
social changes and expanding transportation networks [34]. An increasing number of
cases occurred during the following decades, culminating in the official start of the
epidemic in 1981 [120]. Since that time, 76.1 million people have become infected with
HIV, and 35.0 million have died. 36.7 million people globally were living with HIV in
2016, of which 1.8 million became newly infected and 1 million died [142].
HIV is transmitted when HIV virions from an infected individual contact a
mucosal surface or the bloodstream of an uninfected individual [129]. Rates of infection
vary according to the mechanism of transmission, which include sharing needles, sexual
transmission, mother to child transmission, and other forms of blood contact. Certain
populations are more at risk of infection than others, partially due to differences in rates
of these behaviors. The most at-risk populations include drug users, men who have sex
with men (MSM), and sex workers [142].
Over the past decades, HIV has been the target of an intensive research effort to
find treatments, vaccines, and cures. Thanks to the development of antiretroviral therapy
(ART) and its combination into highly active antiretroviral therapy (HAART), the disease
is currently manageable [97, 99, 112], but no effective vaccine or cure has yet been found.
ART disrupts specific phases of the virus replication cycle, reducing the viral load to
below detectable limits in plasma and reducing transmission rates [3, 28]. However,
the virus persists inside latently inside cells such as CD4+ lymphocytes, macrophages,
and monocytes [2] and in tissue reservoirs [154], and viremia returns if the patient
stops therapy or if their viral population develops drug resistance. HIV rapidly acquires
resistance to individual therapies, which is why HAART is the current standard of care;
a combination of therapies that target different parts of the HIV life cycle make escape
3more difficult. Access to HAART has greatly increased the life expectancy, especially in
high-income countries, and life expectancy continues to improve [139]. ART may also be
used as a pre-exposure prophylactic (PrEP) for high-risk populations [55, 135, 160]. PrEP
could even be used on an intervention basis to identify and treat high-risk individuals [73].
However, most HIV-positive individuals are not receiving treatment. Of the 36.7 million
people infected with HIV in 2016, only 19.5 million people were accessing antiretroviral
therapy because of factors such as expense, lack of access to medical care, social stigma
of being HIV-positive or of accessing ART, and insufficient health and sex education
[142].
Despite its success, HAART has its downsides. It is not curative, so a course of
therapy must be taken for life, administered daily, and monitored for effectiveness. Low-
level viremia may still have unknown long-term consequences. ARTs do not penetrate
nervous tissue, so replication and neuropathology occurs unchecked in those tissues.
It also modulates lipid and glucose metabolism, with potentially deleterious effects.
The long-term effects of HAART itself are unknown, and HIV-positive individuals on
HAART still experience excessive morbidity and mortality [118].
HAART and public health programs have contributed to the decline of AIDS-
related deaths [142]. However, these programs have so far failed to completely halt the
spread of HIV. Crucially, no cure or vaccine against HIV has ever been developed. The
search for a vaccine is particularly important because models suggest that a vaccine that
is only 50% effective would still make a huge contribution to halting the HIV pandemic,
preventing 6.3 million new infections by 2035 [86]. HIV is difficult to treat and has
resisted efforts to develop vaccines and cures for a number of reasons [119]. It evolves
quickly, because it lacks proofreading machinery and has a fast generation time (as
fast as 1.5 days). Viral populations therefore acquire large amounts of genetic diversity
within a single host in a short amount of time [10, 18, 20], which allows it to acquire
4Figure 1.1: HIV-1 virion structure. Scale: approximately 120 nm in diameter. Credit
Thomas Splettstoesser (www.scistyle.com).
drug resistance and evade the body’s immune response. Latent viral DNA in host cells
is not treatable by drugs or other therapies in the bloodstream. Reservoirs of virus
exist intracellularly and within multiple tissues – such as nervous tissue – that are not
accessible to current therapies [132]. In addition to these traits, specific factors relating
to the structure and function of Env and the details of immune response make vaccines
difficult to develop; these details are covered in Sections 1.1.2 and 1.1.3.
Latency makes it a challenge to develop a cure for HIV [78]. Researchers draw a
distinction between a sterilizing cure, which would clear all trace of the infection from
all tissues and cells, and a functional cure, which would suppress viremia and allow the
host to live a normal life, despite the presence of reservoirs of latent virus [23].
1.1.1 Genome, structure, and replication
The HIV virion is shown in Figure 1.1. Its outermost membrane is a lipid bilayer
which is dervived from the host cell when the virion buds from its surface. The membrane
is studded with embedded viral envelope proteins, as well as host proteins from the host
5Figure 1.2: Landmarks of the HIV-1 genome, with genes in all three reading frames.
From https://www.hiv.lanl.gov/content/sequence/HIV/MAP/landmark.html
cell. Inside the envelope is a matrix of protein p17, which has both a structural function
and regulates various parts of the viral life cycle. The matrix contains copies of other
viral proteins, and a capsid of viral protein p24. Inside the capsid are two copies of RNA,
which encode the virus’s genome, plus other viral proteins such as reverse transcriptase
and integrase. Figure 1.2 shows the layout of the genes in the HIV-1 genome. Genes are
encoded in different, sometimes overlapping, reading frames.
The virion reproduces by infecting host cells, reverse transcribing its RNA and
integrating it into the host’s DNA, inducing the host into producing more copies of itself.
gp160 gets cleaved into gp41 and gp120, which are expressed on the surface of the host
cell. The rest of the viral proteins are assembled into a new capsid, which buds from the
surface of the cell as a new virion. The full process is shown in Figure 1.3. CD4-positive
T cells die after infection; other types of cells do not [19]. Each part of the life cycle is a
potential target for anti-retroviral therapy: entry inhibitors prevent binding and fusion;
reverse transcriptase inhibitors inhibit the reverse transcription of viral RNA to DNA,
either by binding to reverse transcriptase or by incorporation into and termination of the
DNA strand; integrase inhibitors prevent the viral DNA from being integrated into the
host DNA; protease inhibitors prevent protease from cleaving precursor proteins.
6Figure 1.3: Replication cycle of HIV. HIV-1 infects a CD4-positive cell,
reverse-transcribes its RNA to DNA, and integrates it into the host DNA. The host
transcribes and translates the viral genes, producing proteins which are cleaved and
packaged into new virions that bud from the surface of the cell and go on to infect more
cells. From [4].
Figure 1.4: Regions of gp160, which codes for both gp120 and gp41. Three copies of
each make up the viral spike Env. From Figure 2 [136].
7(a) The structure of unbound
Env.
(b) Env bound to CD4
receptor.
Figure 1.5: Structure of Env in unbound state, and bound to a CD4 receptor. Structural
visualizations of Env from the Protein Data Bank [7] (www.rcsb.org).
1.1.2 Env
This work is chiefly concerned with Env, because it is the primary target of
neutralizing antibodies. The env gene (Figure 1.4) is a 2.6kb gene that codes for the
gp160 polyprotein. After transcription and translation, the gp160 polyprotein is cleaved
into gp120 and gp41 [44]. The fully-assembled protein, also known as the “viral spike”,
is a trimer of gp120/gp41 heterodimers: three copies of gp41 form the transmembrane
protein, and three copies of gp120 that form the surface protein (Figure 1.5a). The
viral spike is thickly shielded with glycans, hiding it from the immune system until it
is close to a host cell and begins to bind to a CD4 receptor (Figure 1.5b). Env then
undergoes a complex series of conformational changes as it binds to the CD4 receptor
and to a chemokine co-receptor. The virion envelope fuses with the host cell’s membrane,
releasing the payload into the cell and setting the rest of the replication cycle into motion
(Figure 1.6).
Different strains of HIV use different chemokine co-receptors during envelope-
8Figure 1.6: CD4-mediated entry. Env binds to a CD4 receptor and a chemokine
co-receptor. It undergoes a conformational change that brings the viral envelope into
close proximity with the host cell membrane, causing them to fuse. From [153].
mediated entry into the host cell. The ability of a strain to use a particular coreceptor
is known as tropism. R5 viruses use the beta-chemokine CCR5 receptor, which is
expressed on the surfaces of macrophages and T-cells. Almost all HIV subtypes use this
coreceptor, and it has been extensively studied because of its effect on disease progression
[6, 54, 84, 162]. For reasons yet unknown, most transmissions involve R5 virus [129].
X4 viruses use the alpha-chemokine CXCR4 receptor, which is expressed on T-cells.
X4R5 viruses can use both. Moreover, some strains can infect CD4-negative cells via
CXCR4 alone. HIV may also be transmitted directly from cell to cell in vitro, though
whether it occurs in vivo remains a matter of debate [1].
1.1.3 Broadly-neutralizing antibodies
Antibodies are proteins produced or secreted by B cells that recognize and bind
antigens. They either tag pathogens, which are then recognized and attacked by other
components of the immune system, or they can directly neutralize the target. Antibodies
are composed of two identical heavy chains and two light chains, each of which contains
variable and constant regions, as shown in Figure 1.7. The amino acid sequence of the
variable regions determines which antigens are recognized by a particular antibody. B
9Figure 1.7: Antibody structure. From http://what-when-how.com/acp-medicine/
adaptive-immunity-antigens-antibodies-and-t-cell-and-b-cell-receptors-part-1/.
cells code for a huge number of possible antibodies from a limited genetic repertoire
via recombination of multiple V, D, and J genes [22, 92, 149], as shown in Figure 1.8.
Mutations can further increase their variability. The circulating naive B cell repertoire is
capable of recognizing ∼ 109 antigens [26, 89]. The naive repertoire becomes further
specialized by evolution in response to exposure to antigens. This process, known as
affinity maturation, causes naive B cells that have been exposed to their particular antigen
to undergo clonal selection, leading to lineages of evolved B-cell repertoires against
specific threats. In the case of a rapidly-evolving pathogen like HIV, this evolution
proceeds in a complex series of interactions between the evolving B-cell repertoire and
the evolving HIV population.
The host immune system produces antibodies that bind multiple HIV proteins;
however, Env is the only target for neutralizing antibodies. When targeted by neutralizing
antibodies, the viral population quickly evolves escape mutations. This arms race between
the immune system and the viral population is one of the main drivers of the explosion of
genetic diversity after the initial infection, which usually begins with a single founder
sequence [58]. 10-25% of people with HIV develop broadly-neutralizing antibodies
10
Figure 1.8: Somatic recombination in antibody heavy and light chains. From
http://what-when-how.com/acp-medicine/
adaptive-immunity-antigens-antibodies-and-t-cell-and-b-cell-receptors-part-1/.
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Figure 1.9: The main bNAb targets in Env. Broadly-neutralizing antibodies tend to
target one of these five regions in Env. These epitopes may represent weaknesses in Env
from an evolutionary standpoint that could be exploited [152]. From “HIV Vaccine
Research: An update”.
(bNAbs), which are able to bind and neutralize a large number of HIV strains [49]. This
ability makes bNAbs an attractive target of research, since they may provide they key to
vaccine design, as well as antibody-mediated therapies.
Env possesses many characteristics that make it a difficult target for antibodies,
which is why few individuals develop bNAbs, and why the immune response is often
inadequate to prevent the progression to AIDS. HIV’s high mutation rate and fast genera-
tion time allow it to quickly evolve escape mutations, if they were not already present
at low frequencies in the highly diverse population. Cleavage of gp160 into gp120 and
gp41 is inefficient, causing antibodies to target the uncleaved, inactive form. Env is
conformationally flexible and heavily shielded by glycans until fusion begins, at which
point proximity of the host cell inhibits binding. Despite these difficulties, bNAbs do
develop. Five main classes of bNAbs have been discovered, which differ in their target,
as shown in Figure 1.9: the V3-high mannose patch, the V2 apex, CD4 binding site
(CD4bs), the gp41 membrane proximal external region (MPER), and the gp120/gp41
interface, including the fusion peptide [65, 151].
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One promising approach to developing a vaccine would be to induce the de-
velopment of bNAbs in HIV-negative individuals. However, there are currently many
obstacles that need to be overcome before this approach becomes clinically viable
[38, 62, 81, 83, 88]. The conditions that lead to the development of bNAbs are not
generally understood. Naive antibodies bind weakly to HIV, and most evolved antibody
lineages that appear soon after infection are narrowly neutralizing, which means they do
not neutralize a broad number of strains in a neutralization panel. In contrast, bNAbs do
not appear in most cases until after years of infection, suggesting that a complex series of
specific interactions with the evolving Env population are necessary to develop bNAbs.
These lineages may also depend on features of the early variants of Env [61] and on the
genetic background of the host. Finally, even if bNAbs can be successfully induced, they
will need to be maintained at protective levels.
Deep sequencing of B cell repertoires has become a key tool for understanding the
immune response [9, 39, 46, 48, 155, 158], and this approach is currently being used to
understand the process of bNAb development. However, the evolution of B cell lineages
cannot be fully understood except in the context of the Env population that co-evolved
with them. Therefore, there is a similar need for longitudinal deep sequencing of Env
populations. Most sequencing methods are insufficient for this task, because they either
lack depth or they use short reads that lose long-range linkage information that could be
crucial for understanding the evolution and escape. These shortcomings were recently
addressed by deep, full-length sequencing of env with the SMRT sequencing protocol.
1.2 Full-length SMRT sequencing of env
Pacific Bioscience’s single-molecule realtime (SMRT) sequencing is a third-
generation sequencing protocol. Single-molecule methods like SMRT have a number of
13
Figure 1.10: The Pacific Biosciences RS II sequencer. From pacb.com.
Figure 1.11: How SMRT sequencing works. From [35].
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specific advantages over first- and second-generation sequencing technologies, including
speed and read length [121, 124]. This platform is especially useful for viral sequencing
[113].
SMRT sequencing can provides high-quality reads with sufficient length and
depth to study HIV-1 env populations. The details of the effective sequencing depth and
of the single-molecule accuracy distribution depends primarily on the amplicon length,
as described below. For a comparison with other sequencing technologies, see [42].
These qualities make it the best choice currently for sequencing highly diverse amplicon
populations such as HIV-1 env. The work described in this dissertation was done with the
RS II (1.10); these benefits are presumably compounded in the newer Sequel Systems,
which produce about seven times more reads than the RS II.
The entire sequencing process takes place on a silicon chip (SMRTcell) that
contains a large number of microscopic holes called zero-mode waveguides (ZMWs).
Each ZMW contains a single DNA polymerase, allowing a number of molecules to be
sequenced in parallel. SMRTbell adapters are ligated onto the amplicon to form a circular
SMRTbell molecule, which runs through the DNA polymerase repeatedly. Nucleotide-
specific fluorescent tags are observed by a sensor and the fluorescence signal is used for
basecalling. The entire process produces a ZMW read, which contains multiple copies
of the forward and reverse amplicon sequences, interleaved with the adapter sequences.
The individual copies are then combined into a higher-quality consensus sequence called
a circular consensus sequence (CCS). The process is illustrated in Figure 1.11.
SMRT sequencing has a reputation for producing error-prone reads, but the error
rates usually cited (typically around 12-15% [111, 113]) refer to the raw error rate of the
ZMW read. Combining the forward and reverse passes into a single CCS drops the error
rate considerably. The final accuracy of the CCS depends on the length of the amplicon
and the length of the read. The shorter the amplicon, or the longer the read, the more
15
Figure 1.12: SMRT errors rates on NL4-3. (A) Distribution of error rates of full-length
env CCS sequences, for different predicted error rate thresholds. (B) Observed error
rate versus predicted error rate, showing that quality scores are well correlated with the
true error rates, and therefore useful for filtering. Image from [63].
passes get combined into the final CCS, and the higher the quality. Errors tend to be
mostly insertions and deletions, especially in homopolymer regions.
My collaborators at UCSD and Pacific Biosciences recently developed a SMRT
sequencing protocol for full-length env [63]. It is now possible to sequence an entire
population from a single host at multiple time points to infer how the population is
evolving, for instance, in response to bNAbs or therapies that target Env. For full-length
env sequencing, the amplicon is about 2.6kb, yielding a per-read error distribution shown
in Figure 1.12 for the P5/C3 chemistry. Multiple tests confirm the accuracy of the results,
including comparisons with a known NL4-3 template. Moreover, phylogenies obtained
from running our newly-developed pipeline on SMRT sequences agree with Sanger
sequencing, as shown in Figure 1.13.
The sequencing protocol was published in [63], which also contained an early
version of the computational pipeline presented in this dissertation. The method was
validated on NL4-3, as well as donors P018, K453, and H497, and results analyzed with
early version of FLEA. We re-analyzed P018 with the current version of FLEA, which is
described in the next chapter.
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Figure 1.13: Phylogenetic tree of Env from donor PC064. Nodes are colored according
to the longitudinal time point and scaled according to inferred abundance. Sequencing
was done with both the SMRT sequencing protocol and Sanger sequencing, to show
agreement between the two methods. Dotted lines show the locations of Sanger
sequences. Image from [63].
17
Figure 1.14: Phylogenetic trees for Env from three donors from the San Diego HIV-1
Primary Infection Research Consortium (SD-PIRC). Sequenced with SMRT
sequencing and analyzed with the FLEA pipeline. Nodes are colored according to the
longitudinal time point and scaled according to inferred abundance. All three infections
show increased diversity as time goes on. Image from [63].
The sequencing depth and accuracy of this protocol allow researchers to resolve
complex population structures with many closely-related minority variants and to perform
phylogenetic analysis of entire viral populations in a single host. Once the sequencing
technology enabled these experiments, significant computational work was required to
develop the tools to analyze the data coming off the sequencer. Those computational
tools and methods are the subject of this dissertation.
1.3 The rest of this dissertation
Thanks to the full-length sequencing protocol, it is now possible to obtain longi-
tudinal full-length env sequences. That data can be used to aid in rational vaccine design,
tracking the effect of monoclonal antibody therapies on the population, and many other
kinds of population-level work, but processing the sheer number of reads it provides is a
challenge. Each sequencing run is capable of producing around 50,000 reads per time
point. Filtering at a 1% expected error rate and appropriate length yields about 10,000
sequences for the P5/C3 chemistry, and 15,000 for the P6/C4 chemistry. Therefore, a
longitudinal experiment can easily produce over hundreds of thousands of sequences.
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Moreover, the data still contains errors – for instance, even an error threshold of 1% for
a 2.6 kb amplicon still yields an expected 26 errors per sequence – so even if it were
possible to input all the CCSs directly into a suite of analyses, the results would be
biased. For pathogens with low indel variablity, such as HCV, a common strategy is to
pairwise align each read to a reference, stack them into a multiple sequence alignment,
then perform further analyses1 [146]. However, HIV env populations contain a large
amount of indel variation, so this strategy would discard all insertions relative to the
reference and break in highly variable regions.
The subject of this dissertation is a set of computational methods to solve these
problems for longitudinal full-length env sequences. Chapter 2 describes FLEA, a pipeline
for analysis and visualization of a large number of erroneous sequences with indel
variation. Chapter 3 describes RIFRAF, a sequence consensus algorithm that uses quality
scores and an in-frame reference sequence to infer highly-accurate consensus sequences.
Chapter 4 gives an overview of the results acquired so far with FLEA, which has been
used on samples from donors that developed lineages of broadly-neutralizing antibodies,
and on participants in a phase I clinical trial of a monoclonal antibody therapy. Chapter 5
summarizes my work and proposes future directions for this research.
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Chapter 2
FLEA
Abstract
Next generation sequencing of viral populations has advanced our understanding
of viral population dynamics, the development of drug resistance, and escape from host
immune responses. Many applications require complete gene sequences, which can
be impossible to reconstruct from short reads. HIV-1 env, the protein of interest for
HIV vaccine studies, is exceptionally challenging for long-read sequencing and analysis
due to its length, high substitution rate, and extensive indel variation. While long-read
sequencing is attractive in this setting, the analysis of such data is not well handled by
existing methods. To address this, we introduce FLEA (Full-Length Envelope Analyzer),
which performs end-to-end analysis and visualization of long-read sequencing data.
FLEA consists of both a pipeline (optionally run on a high-performance cluster),
and a client-side web application that provides interactive results. The pipeline transforms
FASTQ reads into high-quality consensus sequences (HQCSs) and uses them to build
a codon-aware multiple sequence alignment. The resulting alignment is then used to
infer phylogenies, selection pressure, and evolutionary dynamics. The web application
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provides publication-quality plots and interactive visualizations, including an annotated
viral alignment browser, time series plots of evolutionary dynamics, visualizations of
gene-wide selective pressures (such as dN/dS) across time and across protein structure,
and a phylogenetic tree browser.
We demonstrate how FLEA may be used to process Pacific Biosciences HIV-1 env
data and describe recent examples of its use. Simulations show how FLEA dramatically
reduces the error rate of this sequencing platform, providing an accurate portrait of
complex and variable HIV-1 env populations.
A public instance of FLEA is hosted at http://flea.datamonkey.org. The Python
source code for the FLEA pipeline can be found at https://github.com/veg/flea-pipeline.
The client-side application is available at https://github.com/veg/flea-web-app. A live
demo of the P018 results can be found at http://flea.murrell.group/view/P018.
2.1 Introduction
Next generation sequencing (NGS) has become an invaluable tool for studying
HIV-1 and other rapidly evolving viruses by providing direct high resolution measure-
ments of viral genetic diversity within the host. NGS has been used to study immune
escape [24, 36, 47, 70, 82, 102, 141], drug resistance [40, 50, 51, 69, 91, 137, 141],
transmission bottlenecks [12, 69, 144, 147], population structure and dynamics [36, 41,
47, 59, 76, 108, 133, 157, 159], tropism dynamics [126], and multiplicity of infection
[100]. It is also used in clinical virology [13, 113]. For reviews of the promises and
challenges of NGS applications in virology, see [71], [145], [85], and [5].
Full-length sequences can resolve features that are difficult to assemble from
short sequences [50, 116]. For instance, Pacific Biosciences SMRT sequences were
able to resolve 1.5 kb msg isoforms from Pneumocystis jirovecii, but reads from a 454
22
instrument could not be assembled correctly [116]. For tracking evolutionary patterns in
viral populations, accurately resolving these features provides a more accurate history
of the population, which becomes especially relevant when epistatic interactions and
linkage between mutations effect phenotypic changes in the pathogen [43, 103, 150]. For
example, studies of HIV-1 env frequently use functional assays to measure the potency
with which a given antibody or donor serum neutralizes a specific env strain [123], which
requires knowing the full env sequence.
We have developed a pipeline for handling long read HIV-1 env sequencing data
from within-host viral populations: the Full-Length Envelope Analyzer (FLEA). FLEA
addresses the specific challenges posed by large volumes of such data, e.g., using the
sequencing protocols we previously described in Laird et al [63], which also contains an
overview of a prototype of FLEA. Here we describe the full pipeline and experimentally
demonstrate its ability to resolve populations of closely related variants. FLEA uses state-
of-the-art tools and methods at every step and can be accessed through a web browser or
on a high-performance cluster. FLEA is readily extensible to other genes and systems.
FLEA has recently been used by the authors in two high-profile studies. In [14],
we describe how FLEA was used to process PacBio HIV-1 env data from a clinical trial of
monoclonal antibody 10-1074. For sequences sampled before and after therapy, FLEA
reveals that prior to antibody therapy low-frequency env variants were present with
mutations that typically confer resistance to 10-1074. Additionally, when resistance
emerges, it emerges multiple times, exploiting many different resistance pathways. FLEA
was also used to characterize the longitudinal env population that drove development of a
broadly neutralizing antibodies against the apex of the env trimer, sampled from donor
PC64 from the Protocol C primary infection cohort [65].
There exist dozens of standalone pipelines developed for analyzing HIV-1 and
related sequence data, including longitudinal samples [40, 51, 70, 72]. However, it was
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necessary to develop a new tool due to HIV-1 env’s extensive natural indel variation
and the high rate of indels in long PacBio reads, which are especially problematic when
any spurious indel in the 2.6kb env amplicon corrupts the reading frame, rendering the
sequence uninterpretable. With HIV-1 env, the common strategy of mapping reads to
a reference fails because the diversity in variable regions of env, predominantly driven
by extensive indel processes, means that these regions in sampled reads lack homology
to those in any heterologous reference sequence. Instead, FLEA relies on a fine-grained
cluster-and-consensus strategy to remove spurious indels from reads. The task is related
to Liang et al. (2016), but, rather than distinguishing a small number of variants at
81-91% identity, we must distinguish potentially hundreds of variants that differ by only
a handful of bases.
In addition to a standalone application, FLEA is also available as an online resource
that provides interactive visualizations for all its analyses. To allow researchers to further
examine and dissect their results, FLEA also provides access to raw data, such as aligned
consensus sequences and phylogenetic trees.
2.2 Design and Implementation
2.2.1 Pipeline
The input to FLEA is a set of FASTQ files from the PacBio RS-II or Sequel. Each
set corresponds to one time point, containing circular consensus sequence (CCS) reads,
which can be obtained using the ”Reads of Insert“ protocol on PacBio’s SMRTportal
or SMRTanalysis tools. Upon completion, the FLEA pipeline produces results as JSON
(Javascript Object Notation) files, a standard format for machine (and human-) read-
able structured data. The logic of FLEA is implemented in Nextflow [27], a workflow
framework for deploying parallel pipelines to clusters and clouds.
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CCS
time point 1
Quality pipeline
QCS
Consensus pipeline
HQCS +
copynumbers
CCS
time point 2
Quality pipeline
QCS
Consensus pipeline
HQCS +
copynumbers
CCS
time point N
Quality pipeline
QCS
Consensus pipeline
HQCS +
copynumbers
. . .
Alignment pipeline
Multiple sequence alignment
Analysis pipeline
Analysis results
Figure 2.1: Overview of the FLEA pipeline, broken into conceptual sub-pipelines. The
Quality and Consensus sub-pipelines process each time point separately. Duplicate
steps in other time points are grayed out. CCS stands for “circular consensus
sequences”; QCS for “quality-controlled sequences”, and HQCS for “high-quality
consensus sequences”.
FLEA consists of multiple sub-pipelines, as shown in Fig. 2.1. Details of the quality
and consensus pipelines are depicted in Fig. 2.2. Together, these two pipelines take error-
prone CCS reads and convert them into unique high-quality consensus sequences. The
alignment pipeline generates a multiple sequence alignment, which is used by multiple
methods in the analysis pipeline.
2.2.2 Quality assurance sub-pipeline
The first steps remove low quality reads and filter out common sequencing
artifacts. Parameters given in these steps were chosen for full-length HIV-1 envelope
sequences from the RS-II or Sequel platforms. Other reads with different properties (error
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Figure 2.2: Quality and consensus sub-pipelines. These steps are repeated
independently on each time point. Numbers are reported from the analysis of sequences
from the first time point (V03) of donor P018, which is three months post infection.
Percentages give the fraction of sequences retained after filtering. Tasks indicate
whether they use third-party tools USEARCH or MAFFT.
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Figure 2.3: Hidden Markov model used for trimming poly-A and poly-T heads and
tails. A head and tail states have a small (p = 0.01) probability to emit non-A bases,
and similarly for T . The body state emits all four bases with equal probability. The
start, and stop states emit nothing.
rates, error models, lengths, homopolymer distributions, etc.) likely require different
parameters. All steps are run independently per time point.
1. Filter by error rate. The input FASTQ files contain Phred scores for each base,
encoding the probabilities of incorrect base calls. USEARCH [30] is used to remove
reads with an expected error rate greater than 1%, computed as the mean of the
per-base error probabilities.
2. Trim heads/tails. A fraction of reads from the Laird et al. sequencing protocol
contain poly-A or poly-T heads or tails (cause unknown), which can be hundreds
of bases long and sometimes contain a small number of other bases.
These heads and tails are trimmed with a hidden Markov model (Fig. 2.3) imple-
mented in Pomegranate [53]. The emission probabilities of the model were fixed,
and the transitions trained using Baum-Welch. The Viterbi path for each sequence
is computed, and bases emitted by head and tail nodes are removed.
3. Filter long runs. Reads with homonucleotide runs longer than 16 bases are
discarded. This length was chosen to be twice the length of the longest such run in
the LANL HIV database [37].
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4. Filter contaminants and trim reads. Sample contamination can introduce non-
native sequences that interfere with subsequent analyses, so these contaminants
must identified and discarded. USEARCH is used to compare reads to a contaminant
database and a reference database using usearch global. Alignments returned
from querying the database are then used to trim reads to the gene boundaries.
Trimming terminal insertions is vital for the accuracy of downstream tasks, such as
length filtering and clustering.
The contaminant database contains HXB2 and NL4-3 env, each ubiquitous in labs
working with env sequences and a common source of sample contamination. Reads
that match with ≥ 98% identity are discarded. Since a 1% error rate cutoff was
earlier used, this parameter conservatively ensures that these contaminants are
almost certainly identified.
The reference database contains thirty-eight sequences representing the major
HIV-1 Group M subtypes from the LANL sequence database [37]. Reads with
≤ 70% identity to every sequence in the reference database are discarded. This
cutoff is chosen to retain reads remotely similar to HIV-1 Group M while excluding
contaminants such as human or bacterial genome reads. If a sample is from SIV,
or from a non group-M HIV+ donor, then more appropriate reference sequences
should be added to the database.
5. Filter by length. By default, sequences shorter than 90% or longer than 110%
of the length of the reference sequence are discarded. However, sequences with
large deletions are frequently observed in HIV. These likely represent replication
incompetent envelopes, and their reduced length can cause them to be dramatically
oversampled due to PCR length bias. Users who want to include these species in
their analyses should modify these parameters.
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Reads that pass this quality assurance phase have low expected error rates and
no homonucleotide runs, are within 70% identity of at least one reference sequence, are
(after trimming) no more than 10% different in length than a reference sequence, and do
not match the contaminant database. We refer to these sequences as quality-controlled
sequences (QCS).
Consensus sub-pipeline for variant identification
Even for highly diverse populations, unique reads in a sequencing run outnumber
the true unique variants, predominantly due to sequencing errors. The problem is far more
significant in long reads than in short reads, precluding the use of amplicon denoising
strategies used to reduce error rates in short read sequencing [31]. To accommodate this
effect, the next phase of the FLEA pipeline clusters and combines QCS reads, attempting to
infer the true variants in each time point. It also attempts to detect and correct frameshift
errors.
1. Cluster. USEARCH is used with the cluster fast command to generate clusters
with 99% nucleotide identity. This parameter approximates the 1% error cutoff
used in the error rate filtering step, so that pairwise distances of sequences in the
same cluster are consistent with the sequencing error. cluster fast runs in a
single pass, so it is sensitive to input order. Sequences are sorted from lowest to
highest quality according to expected error rate; experiment suggests that this order
yields better results (see supporting information).
2. Select and subsample clusters. Clusters with fewer than three members are
discarded, because they are too small to de-noise by majority consensus. Clusters
with more than 50 members are subsampled to the top 50 with the lowest expected
error rate to speed up the multiple sequence alignment step.
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3. Align and consensus. MAFFT [57] is used to align each cluster. The consensus
sequence of each alignment is computed.
4. Frame correction In-frame consensus sequences from all time points are collected
into a USEARCH database for frame correction. usearch global is then used to
align each out-of-frame sequence to its top hit. The nucleotide alignment is used
to correct incomplete codons: short insertions (1 or 2 base pairs) are discarded,
and single deletions are replaced with the aligned base. Sequences with longer
insertions or deletions are discarded. All changes are logged, so that the user can
identify the sequences that have been corrected.
5. Uniqueness Non-unique consensus sequences are dereplicated using usearch
--fastx uniques.
6. Copy numbers The number of sequences per cluster provides an estimate of the
relative abundance of that HQCS in the population. Those numbers are further aug-
mented by adding sequences orphaned by cluster filtering and HQCS dereplication.
usearch global is used to assign each QCS to its nearest HQCS. The number of
sequences accrued by each HQCS is interpreted as its copy number.
All of these tasks are run separately for each time point, yielding sets of unique in-frame
consensus sequences. We refer to these sequences as high-quality consensus sequences
(HQCS).
Alignment sub-pipeline
The HQCSs from all time points are combined into a single file, translated to
protein sequences, and aligned using MAFFT. A Python script then transfers the gaps from
each aligned protein sequence to the corresponding nucleotide sequences to produce a
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codon-level nucleotide multiple sequence alignment of all unique variants from all time
points.
Analysis sub-pipeline
The analyses used in FLEA take as input the two outputs of the alignment phase:
a codon multiple sequence alignment of all unique HQCS sequences from all time points,
and their associated copy numbers. These data are used for the following analyses.
1. Time point metrics. HyPhy [107] scripts are used to compute evolutionary metrics
(total, dN, and dS divergence and diversity) and phenotypic metrics (protein length,
potential N-linked glycosylation sites, isoelectric point) for each annotated region
(e.g., V1, MPER) in the amplicon for each time point.
2. MRCA. The most recent common ancestor is inferred by taking the copy-number-
weighted codon consensus of the codon-aligned HQCSs from the earliest time
point. By including gaps, the MRCA sequence is already aligned with the rest of
the multiple sequence alignment. This strategy is acceptable for primary infection
studies from single founders with very low early diversity.
3. Reference coordinates. MAFFT is used to assign HXB2 [115] coordinates to the
gapped MRCA sequence, which are then transferred to the full multiple sequence
alignment.
4. Infer phylogeny. A maximum-likelihood phylogenetic tree is inferred with Fast-
Tree2 [109, 110] under the general time reversible model.
5. Ancestral sequence reconstruction. HyPhy is used to infer ancestral sequences at
the internal nodes of the phylogeny, using joint maximum likelihood reconstruction
and the HKY85 substitution model [45].
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6. Multidimensional scaling. TN93 [127] is used to compute a distance matrix for
all HCQC sequences using the Tamura Nei 93 distance [138]. Metric multidi-
mensional scaling [140] (implemented in scikit-learn [21]) is used to find a
two-dimensional embedding of the sequences that approximates their pairwise
distances.
7. FUBAR. Site-specific selection rates are inferred using FUBAR [93], implemented
in HyPhy.
8. Position-specific changes. Entropy and Jensen-Shannon divergence are computed
for each position in each time point.
The results of these analyses are provided to the user in an interactive web
application, described next.
2.2.3 Web application
The FLEA web app is built using modern web design principles. It consists of two
parts: a Javascript client-side app, written using the Ember.js [33] framework, and a
server-side REST (REpresentational State Transfer) service for serving JSON-formatted
data. There are two main benefits to using this decoupled pattern for scientific web
applications. First, the client-side code only needs to be downloaded once, at the start
of the session. The data are requested from the server and cached as needed. Once
everything is loaded, the visualizations run entirely in the browser with no delays for
page loads. Second, the REST service may be reused by other apps and third-party tools.
The web app presents the results of the FLEA analysis as a series of interactive
visualizations. The report is organized into the following sections.
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Multidimensional scaling. A two dimensional embedding of the HQCSs is visualized
as a bubble plot, showing changes in population structure over time, as shown in Fig. 2.4.
This visualization has been especially useful for investigating populations with super-
infection, or with multiple founders, where aggressive recombination between vastly
different env variants precludes the use of phylogenies.
Figure 2.4: Screenshot of the multidimensional scaling plot. The embedding in two
dimensions preserves pairwise evolutionary distances between HQCSs. Node area is
proportional to copy number, and color corresponds to time point. The increasing
genetic diversity of the population is visible as time goes on.
Evolutionary trajectory. The evolutionary trajectory viewer plots evolutionary and
phenotypic metrics for each time point and multiple regions in the amplicon, giving a
high-level overview of population dynamics over time. Fig. 2.5 shows the plot for the
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Figure 2.5: Screenshot of the evolutionary trajectory report. Four evolutionary metrics
(dS divergence, dN divergence, total divergence, and total diversity) and two phenotype
metrics (length and possible N-linked glycosylation sites) are shown for gp160.
entire gp160 region of HIV-1 Env, which is generated with the D3.js plotting library
[87].
Sequences. The multiple sequence alignment of all the HQCSs sequences is the foun-
dation for all subsequent analyses. It is displayed in the amino acid sequences viewer,
which contains a custom alignment browser and an interactive motif dynamics plot, as
shown in Fig. 2.6.
Protein structure. The protein structure viewer maps evolutionary metrics to an in-
teractive three-dimensional structure of the protein, customized from PDB ID 5FUU, a
recently resolved cryo-EM structure [68], and rendered using pv [77]. Missing residues
are rendered as spheres which are positioned by Be´zier curve interpolation. dN/dS ratios,
Jensen Shannon divergence, and entropy may all be mapped to the protein structure, as
shown in Fig. 2.7. The same metrics are also plotted in one dimension for each time
point, as shown in Fig. 2.8. The protein visualization interacts with the sequence viewer
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Figure 2.6: Screenshot of amino acid sequences viewer. Sequences are grouped by
identity, with aggregate copy number and population percentage shown to the right. An
overview of the amplicon, optionally annotated with region names, provides fast access
to different locations of the alignment. Selecting columns of the alignment interactively
updates the amino acid dynamics plot, showing the dynamics of the selected motif over
time. In this case, the trajectory shows changes in the N332 glycan supersite. Sites
inferred by FUBAR to be undergoing positive selection are selectable.
by showing alignment positions and highlighting the residues in the selected sequence
motif.
Trees. The tree viewer renders a tree browser with phylotree.js [128], as shown in
Fig. 2.9. Leaf nodes are scaled to the copy number of their sequence. The tree zoom
level, layout, and coloring is interactively modifiable. Motifs selected in the sequence
viewer are mapped to the tree. Ancestral nodes are colored by motif, allowing inferred
changes to be tracked through the entire phylogeny.
35
Figure 2.7: Screenshots of the interactive three-dimensional Env structure, colored
according to JS divergence (left) and dN/dS values (right). Positions imputed to be
undergoing more positive selection (dN/dS > 1) are darker red, and positions
undergoing more purifying selection (dN/dS < 1) are darker blue. The right structure
also shows motif positions highlighted in the sequence viewer.
2.3 Results
The entire pipeline was run on HIV-1 env reads from donor P018, which are
available from the NCBI Sequence Read Archive under BioProject PRJNA320111, and
were sequenced as part of [63] on the RS-II instrument, using the older generation P5/C3
PacBio sequencing chemistry. The full dataset contains 58,468 CCS reads. The reads
are split across six time points, which are coded as V03, V06, V12, V22, V33, and V37,
where V x corresponds to a visit x months post infection. The number of reads per time
point ranges from 7,530 in V33 to 11,806 in V06.
2.3.1 Results on simulated data
The true sequences and copy numbers are not known for the P018 data. In order
to assess the accuracy of our inferred sequence population, we used the HQCSs from
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Figure 2.8: Screenshot of dN/dS values mapped to protein positions and separated by
time point.
a previous FLEA run to simulate a gold standard dataset on which to assess the FLEA
pipeline.
The simulation procedure starts with the HQCSs and copy numbers from the
FLEA results on P018, then augments them with additional mutated sequences to create a
gold standard set of templates. Mutated sequences were added because our clustering
strategy may artificially merge similar templates. For each template, noisy reads with a
SMRT-style error profile were sampled. Full details of the simulation process appear in
the supporting information. These simulated reads were sent through the FLEA pipeline,
both with and without frame correction.
The resulting QCS and HQCS sequences were compared to the ground truth
using Earth Mover’s Distance (EMD), using normalized copy numbers for the population
weights and edit distance for the distance matrix. The fully constrained EMD has
units that can be directly interpreted as the average change per nucleotide necessary to
transform one sequence population into another. We also calculate two variants of EMD
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Figure 2.9: Screenshot of the phylogenetic tree viewer. Leaf node size corresponds to
sequence copy number. Node color corresponds to time point. Since ancestral
sequences have been inferred, ancestral nodes are colored according to the selected
motif, which in this case is the N332 glycan supersite.
for further insight into how well the inferred population B estimates the sequences in the
ground truth population A. EMDFP removes the constraint on A, allowing any amount
of flow from A to B. It is a measure of false positives because it grows when B contains
extra sequences distant from any in A. Similarly, EMDFN removes the constraint on B.
It grows when B fails to recapitulate sequences in A, and therefore is a measure of false
negatives.
To see the effect of sequencing runs of different depths, the experiment was
repeated for 300, 1,000, 3,000, and 10,000 reads per time point. The results, which
appear in Table 2.1, show the benefit of FLEA’s approach of reducing sequence errors
via clustering and consensus. The QCS sequences, although they have few false nega-
tives (EMDFN = 0.0782) for n = 10,000, are dominated by false positives (EMDFP =
8.3). However, adding the consensus sub-pipeline virtually eliminates false positives
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Table 2.1: EMD metrics for various numbers of reads, averaged across all time points.
“mean errors” gives the average number of errors in the reads, estimated from the
simulated Phred scores.
n mean errors consensus type EMD EMDFP EMDFN
300 9.63 QCS 12.3769 8.3418 2.8956
HQCS 7.1570 0.4050 5.4271
HQCS (corrected) 6.4752 0.3020 4.5533
1000 9.63 QCS 10.5433 8.3686 1.2551
HQCS 2.8279 0.0610 1.1453
HQCS (corrected) 2.7557 0.0666 1.0405
3000 9.6 QCS 9.5053 8.2837 0.3908
HQCS 1.6432 0.0146 0.4322
HQCS (corrected) 1.5168 0.0045 0.2925
10000 9.56 QCS 9.0734 8.3080 0.0782
HQCS 1.0549 0.0336 0.1735
HQCS (corrected) 1.0146 0.0073 0.1463
(EMDFP = 0.0336), at the cost of only a 2.4x increase in false negatives, for a 8.6x im-
provement in EMD to 1.0549. The frame correction step further improve both EMDFP
and EMDFN because it turns false positives into true positives.
The full-length env sequencing protocol yields approximately 10,000 reads per
run; the P018 data averaged 9,744 reads per time point. Therefore, these results with
n = 10,000 suggest that FLEA is capable of taking a full sequencing run of CCS reads
from a diverse viral population with an average of 9.56 errors per sequence and inferring
HQCSs with an average of 1.01 errors per sequence, which corresponds to an average
error rate of 0.038%. Moreover, these error rates are mostly caused by low-abundance
sequences in both the true population and the inferred FLEA sequences. Figure 2.10
shows that FLEA perfectly recovers all sequences from all time points that account for at
least 1.6% of the population.
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Figure 2.10: Comparison of true sequence abundances versus copy numbers inferred
by FLEA for each time point of the simulated P018 data. Each node represents one
sequence, with the area denoting its relative abundance in the population. The true
population (top) is colored green. For each true sequence, the matching HQCS
sequences appears below it in blue. Red nodes denote false negatives and positives. The
most common false negative for each time point is annotated with its abundance.
2.3.2 Results on real data: donor P018
FLEA was run directly on the P018 sequences, and the results are summarized here.
The full results of this run are available to view at http://flea.murrell.group/view/P018.
Fig. 2.2 shows the number of sequences from the V03 time point that make it
to each stage of the quality and consensus pipelines . At three months post infection,
the majority amino-acid sequence variant is shared by 52.1% of the population, and the
next most common variants accounts for just 8.66%. This relative lack of diversity is
consistent with early infection dynamics. By 37 months post infection there is much
more diversity: the most common variant accounts for only 3.96% of the population.
Donor P018 shows signs of potential N332 glycan specificity, as shown by the
motif trajectories in Fig. 2.6. The glycan supersite, centered around N332 in V3, is a
common target for broadly-neutralizing antibodies [64] because they are often conserved,
so mutations in these regions are associated with escape [25]. A year into sampling
(V12), mutations 328R and 330H dominate, and the majority of sequences also contain
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339N from 22 months (V22) onwards.
2.4 Discussion
The FLEA pipeline analyzes longitudinal full-length env sequences and provides
visualizations of the results. Using simulations, we show that FLEA is capable of inferring
accurate HIV-1 env consensus sequences and population frequencies. Despite each CCS
read containing an average of ten errors, our approach distinguishes variants that differ
by as little as one base from an amplicon with high indel variation. It uses those high-
quality consensus sequences to generate a codon-aware multiple sequence alignment of
all time points, estimate ancestral sequences, infer the phylogenetic tree, and perform
many other population-level analyses with high accuracy. These results are presented
in a visualization suite that is highly general and applicable to many related sequencing
problem.
While our USEARCH-based clustering and consensus strategy for de-noising long
PacBio amplicons performs well when error rates are < 1%, there is a clear need for
more sophisticated long-read de-noising algorithms that exploit the additional depth of
lower quality reads that we currently discard. This will be especially beneficial for longer
PacBio amplicons, because the CCS read quality distribution degrades with length. For
example, while we can currently obtain around 15,000 CCS reads < 1% from a P6/C4
RS-II run of our 2.6kb env amplicon; this read count drops to ∼ 1,000 for full-length 9kb
HIV genomes.
Both the pipeline and client-side visualizations are under development, with
many improvements planned, including a novel clustering algorithm that reduces false
positives and a novel consensus algorithm that uses quality scores and performs frame
correction. We plan to integrate epitope prediction into the FLEA pipeline and add
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appropriate visualizations for the case when users have IC50 values available for their
sequences. Finally, FLEA will be expanded to support other amplicons.
2.5 Supporting Information
2.5.1 Simulation method
The simulation procedure begins with a population of copynumber-weighted
HQCS sequences from a real FLEA run. The population is augmented with mutants of the
input sequences, to ensure that the simulated ground truth population contains sequences
that differ by only a few bases. Each HQCS has a p = 0.2 probability to donate 30% of
its abundance to a closely-related mutant, which contains one, two, or three substitutions
with equal probability. This mutated population is treated as the ground truth for all
experiments.
In order to simulate sequencing at different depths, different numbers of N reads
are drawn from the same ground truth population for each time point. For each value of
N (300, 1,000, 3,000, and 10,000 in this paper), and for each time point, N sequences are
sampled with replacement from the copynumber-weighted population. Each read is then
mutated with an error model derived from true Pacific Biosciences sequences, in order to
mimic the errors introduced by sequencing, especially homopolymer length errors.
To simulate a read r from template t, it is necessary to model both r itself and
its Phred scores. First an error rate p is drawn from p ∼ Gamma(α = 2,θ = 0.0017).
The length n for each run of identical bases in t (including singletons) is lengthened
or shortened with equal probability to be m = max(n± ε,0), where ε ∼ Poisson(λ =
p/c ·n1.5). c is calibration parameter chosen in these experiments to be 1.55 to match
observed errors. This process introduces homopolymer length errors, which account for
most of the error in Pacific Sciences reads. Then point mutations are introduced at each
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position with probability p/4 of occurring and equal probability for each nucleotide.
Finally, error probabilities are computed for each base as P = p/4+m1.5/m,
which is the per-base mutation rate plus a homopolymer error rate. The final simulated
Phred scores are obtained by adding error per-base errors ε∼N (0,0.1) in the natural
log domain to these probabilities, then converting to Phred scores.
2.5.2 Sequence order for clustering
USEARCH’s cluster fast algorithm runs in a single pass, and therefore is sensi-
tive to the order of the input sequences. We investigated four different strategies: none
(no re-ordering), shuffle (randomly shuffle the sequences), sort (sort from high to low
quality, as measured by expected number of errors), and reverse sort (sort from low to
high quality). Ten trials of simulated sequencing were run to generate 3,000 reads. FLEA
was run on each dataset with all four ordering strategies.
The results clearly favor reverse sorting, as shown in Table 2.2, which does better
on average across the ten trials, and in the worst case it does much better. In the worst
case, other methods suffer from false negatives, as shown in Table 2.4. We hypothesize
that this behavior is caused by reads from the rare templates – which have a low chance of
having a high-quality representative read – loading onto the nearest high-quality template.
Table 2.2: EMD score statistics for different ordering strategies, summarized over ten
trials.
strategy min median max
none 1.161733 1.754568 4.650523
shuffle 1.042900 1.877201 15.177280
sort 1.362890 2.170702 15.585899
reverse sort 1.077585 1.495208 2.853009
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Table 2.3: EMDFP score statistics for different ordering strategies, summarized over
ten trials.
strategy min median max
none 0.0 0.012702 0.726121
shuffle 0.0 0.005160 0.634556
sort 0.0 0.019261 0.839726
reverse sort 0.0 0.005992 0.079191
Table 2.4: EMDFN score statistics for different ordering strategies, summarized over
ten trials.
strategy min median max
none 0.109267 0.363806 4.064444
shuffle 0.104379 0.359525 13.443283
sort 0.170185 0.623503 13.672487
reverse sort 0.096213 0.233316 1.011137
2.5.3 Pipeline visualizations
Nextflow provides pipeline introspection and performance tools including tracing
reports, task order graphs, and timeline visualizations (Figure 2.11).
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Figure 2.11: Timeline of each task in the FLEA pipeline. Tasks are annotated with time
per task and max memory used. Image generated with Nextflow’s -with-timeline
option.
Chapter 3
RIFRAF
Abstract
Motivation: Protein coding genes can be studied using long-read next generation
sequencing. However, high rates of indel sequencing errors are problematic, corrupting
the reading frame. Even the consensus of multiple independent sequence reads retains
indel errors. To solve this problem, we introduce RIFRAF, a sequence consensus algo-
rithm that takes a set of error-prone reads and a reference sequence and infers an accurate
in-frame consensus. RIFRAF uses a novel structure, analogous to a two-layer hidden
Markov model: the consensus is optimized to maximize alignment scores with both
the set of noisy reads and with a reference. The template-to-reads component of the
model encodes the preponderance of indels, and is sensitive to the per-base quality scores,
giving greater weight to more accurate bases. The reference-to-template component of
the model penalizes frame-destroying indels. A local search algorithm proceeds in stages
to find the best consensus sequence for both objectives.
Results: Using Pacific Biosciences SMRT sequences of NL4-3 env, we compare our
approach to other consensus and frame correction methods. RIFRAF consistently finds a
45
46
consensus sequence that is more accurate and in-frame, especially with small numbers
of reads. It was able to perfectly reconstruct over 80% of consensus sequences from as
few as three reads, whereas the best alternative required twice as many. RIFRAF is able
to achieve these results and keep the consensus in-frame even with a distantly related
reference sequence. Moreover, unlike other frame correction methods, RIFRAF can detect
and keep true indels while removing erroneous ones.
Availability: RIFRAF is implemented in Julia, and source code is publicly available at
https://github.com/MurrellGroup/Rifraf.jl.
Contact: bmurrell@ucsd.edu
3.1 Introduction
The problem of finding the consensus of a set of sequences is fundamental to
bioinformatics, especially in the age of high-throughput sequencing. This paper addresses
the task of reconstructing an unknown true sequence from a set of error-prone reads.
Many algorithms that solve this task focus on de-novo or reference-guided assembly of
short reads [96, 101, 104]. However, with the advent of third-generation single-molecule
sequencing technologies, such as Pacific Biosciences’ SMRT sequencing protocol [32],
it is now possible to perform full-length sequencing of entire genes or small genomes.
Here we will focus on finding the consensus of a set of amplicon sequences - where
the sequences have the same start and end points. An example application would be
targeted sequencing of an entire gene from a viral population (eg. [63]). We focus just
on the consensus reconstruction problem, assuming that reads have first been grouped by
genetic identity, either using primer ID barcodes [52, 131], or some form of clustering.
Consensus sequences found via multiple sequence alignment may be inaccurate
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when there are few reads available, or when the reads contain many errors. SMRT se-
quencing in particular is known to contain mostly indel errors, especially in homopolymer
runs. For example, in [63], we discovered that 80% of the sequencing errors were indels.
If these indels carry over into the consensus sequence, they cause frameshift errors which
corrupt the reading frame, and render the amino acid sequence uninterpretable. If a
reference sequence with a trusted reading frame is available, it can be exploited to inform
the consensus.
Current approaches that attempt to reconstruct in-frame consensus sequences
consider these problems separately. There are approaches to infer the consensus of
multiple reads, and there are approaches to correct the reading frame of an already-
inferred consensus sequence. Here, we solve these problems jointly, simultaneously
considering evidence from the reads and the reference sequence.
One common approach to inferring consensus sequences is from multiple se-
quence alignments (MSAs), from which the consensus is calculated by taking the most
common base in each column. A myriad of multiple alignment algorithms are available
[106], any of which may be used for this task. This paper uses MAFFT [56, 57] as an
example of this strategy when comparing alternatives. A multitude of tools, such as the
cons command in EMBOSS [117], are available for computing the consensus of these
alignments. Another approach is to use a partial order alignment [67] representation
of the set of sequences, and find the consensus sequence using dynamic programming
to extract the heaviest bundles [66]. This paper uses poaV21 for comparison. Other
implementations of this approach include pbdagcon2, which was released by Pacific
Biosciences specifically for raw SMRT sequence reads, and nanopolish [74], which
wraps poaV2 for Oxford Nanopore reads. Finally, specialized consensus methods are
available for specific sequencing technologies; these methods model the specific behavior
1https://sourceforge.net/projects/poamsa/
2https://github.com/PacificBiosciences/pbdagcon
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of their target protocol, such as read length and error model. In this domain, Pacific
Biosciences developed the Quiver [17] and Arrow algorithms3 for building circular
consensus sequences from raw ZMW reads.
Existing approaches for reading frame correction (such as FrameBot, which we
use here as a comparator) exploit frame-aware codon alignment to a protein reference,
followed by inserting or deleting bases in the target sequence [148]. Related algorithms
include FALP and LAST [130], Frame-Pro [29], HMMFrame [161], and others. Another
approach is hybrid sequencing, which supplements long single-molecule reads with short
reads [106]. Methods such as HGAP [17] use hybrid sequence data to find and remove
indels.
This paper introduces a new method for inferring consensus sequences of such
reads: the Reference-Informed Frame-Resolving multiple-Alignment Free consensus
algorithm (RIFRAF). RIFRAF considers evidence from both the reads and the reference
simultaneously, allowing reads to inform the frame correction process, and is sensitive
to the read quality scores to ensure that high-quality bases are more informative. These
features allow RIFRAF to make highly accurate predictions, even for a small number
of error-prone reads. Unlike other frame-correction methods, RIFRAF can detect true
frameshift-causing indels and keep them while removing spurious indels.
3.2 Methods
RIFRAF addresses the following sequence consensus problem. Let t be an un-
known template sequence, which is sequenced N times to generate a set of N pairs of
reads and quality scores R = {(si, pi)}Ni=1. Each read si is a noisy observation of t, and
each pi is a vector of error probabilities, one for each base in si. The ith character in read
3https://github.com/PacificBiosciences/GenomicConsensus
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s is denoted si, and the substring from the ith to the jth character is denoted si... j. pi is
the probability that si is an error; an error at a base is either a substitution, an insertion,
or a deletion has occurred next to it. The task is to infer a consensus sequence c that
matches the unknown t. Additionally, we also consider a reference sequence r and prefer
that c not contain insertions or deletions that change its reading frame relative to r. This
is especially useful when the template that generated the reads in R had an intact reading
frame, but the reads themselves have a high indel rate.
r
t
s1, p1 s2, p2 s3, p3 · · · sN , pN
Figure 3.1: Structure of the full model. The unknown template t (grey) has the same
reading frame as known reference r. The sequencing process generates error-prone
reads s1 . . .sN with quality scores p1 . . . pN .
The structure of the full RIFRAF model is shown in Figure 3.1. It infers the
unknown template by optimizing two objectives: the quality-aware alignment to the
reads, and a frame-aware alignment to the reference. The optimization procedure starts
with an initial consensus sequence and proceeds in an iterative greedy manner, mutating
the consensus sequence at every step to improve those objectives. RIFRAF uses a number
of techniques to speed up convergence: filtering mutations, accepting multiple mutations,
forward and backward alignments, banding, batching, increasing indel penalties, and
multi-stage optimization.
RIFRAF is implemented in Julia [8], a high-level scientific computing language.
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3.2.1 Objective 1: pairwise alignment to reads
In order to find the optimal consensus, it is necessary to assign a score to can-
didates. RIFRAF scores consensus sequences by a global pairwise alignment [98, 134]
of each read s with the current values of c. Let A be the |s|+ 1× |c|+ 1 dynamic
programming matrix for aligning c and s. Each ai, j is the score of aligning prefix s1...i
to prefix c1... j. a0,0 is initialized to 0, and the last cell a|s|+1,|c|+1 contains the score
for the full alignment. The score function for c and s is defined as the full alignment
score: S(c|s) = a|s|+1,|c|+1. The overall score of consensus sequence c is the sum over
the alignment scores for all reads: S(c|R ) = ∑(s,p)∈R S(c|s).
The sequencing process has an error rate ρ, which by assumption can can be
partitioned into ρ = ρmismatch +ρinsertion +ρdeletion. These parameters account for the
different error profiles of different sequencing technologies. For instance, in SMRT
sequencing, indels are more likely than substitutions. The base move scores for the
alignment are derived from these error probabilities.
Typical pairwise alignment uses fixed scores for moves. However, RIFRAF also
incorporates sequence qualities into the move scores to generate more accurate alignments.
The scores for match, insertion, and deletion moves depend on the error probabilities p in
the following way. Let q = log10 p (base 10 is used instead of the usual natural logarithm
for compatibility with quality scores such as Phred scores). Let qmismatch = log10ρmismatch,
and similarly for the others. Then move scores are calculated as follows
• A diagonal move from ai−1, j−1 to ai, j has score log10(1− pi) if si = c j (ie. a
match), else qmismatch+qi (ie. a mismatch).
• A vertical move (insertion relative to c) from ai−1, j to ai, j has score qinsertion+qi.
• A horizontal move (deletion relative to c) from ai, j−1 to ai, j has score qdeletion+
max(qi+qi+1). If i = 0, the score is just qdeletion+q1; similarly, i = |s|, the score
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is just qdeletion+q|s|.
Intuitively, the penalties for mismatches, insertions, and deletions are more severe
when the consensus does not match higher quality regions of the reads. PHRED values
are capped at 30 because rarer sources of error that are not sequencing errors (eg. PCR
errors) may have very confident PHRED scores, and we do not wish these to be overly
informative. This cap can be adjusted if these sources of error can be ruled out (for
example if PCR was not used to generate the amplicon library).
The best consensus c∗ under Objective 1 (pairwise alignment to reads) is the one
that maximizes S(c|R ).
3.2.2 Objective 2: Frame-aware alignment to reference
To perform frame correction, RIFRAF requires a reference nucleotide sequence r,
which is known to be in-frame. It models the reference sequence r as having diverged
from the template t, where the differences between r and t represent evolutionary events,
not sequencing error as in Objective 1. The score for the consensus-reference alignment
is modified to reflect this difference. First, two new moves are allowed during alignment:
codon insertion and codon deletion, each with their own penalty, as shown in Figure 3.2.
Second, a new parameter tindel is used as a multiplier for the non-codon insertion and
deletion penalties. Together, these two modifications bias the alignment to prefer only
codon indels, keeping the consensus in-frame. Because it uses nucleotide alignments,
this method works may be expected to work better with more closely related reference
sequences, where nucleotide similarity is preserved.
We first let RIFRAF converge to a draft template c without the reference sequence.
This draft template is used to approximate the divergence between the true template and
the reference, taking the edit distance normalized by the max length d(r,c)/max(|r|, |c|)
to obtain a per-base probability of template/reference disagreement (which is used in the
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ai, j
ai−1, j−1
ai, j−1
ai−1, j
ai, j−3
ai−3, j
Figure 3.2: Codon moves in the reference alignment dynamic programming matrix.
The goal is to favor a consensus that preserves the reading frame. Thus, in addition to
the usual single match, insertion, and deletion moves, codon insertions and deletions
are also allowed, with a lower penalty than single-base indels.
same manner as the per-base quality scores p in Objective 1). Reference (mis)match,
indel, and codon error rates are provided as parameters, and the scores for each move are
computed from error rate ρ as log10(ρ), as before.
The insertion and deletion scores are multiplied by a penalty tindel , which controls
the influence of single insertions and deletions in the reference alignment. If tindel is small,
frame-destroying indels may appear in the consensus, but if it is large, the consensus will
be forced into the reference reading frame, even if the unobserved template really did
contain indels. As we show in Section 3.3, this penalty can be tuned to discard spurious
indels while keeping true ones.
RIFRAF combines both objectives into a single score, allowing the reads to inform
the frame correction. The score of the consensus to reference alignment is denoted
Sr(c|r), and the full score function is:
S(c|R ,r) = S(c|R )+Sr(c|r).
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3.2.3 Optimization procedure
An exhaustive search for the optimal consensus c∗ would be intractable, so
RIFRAF uses a variant of the following greedy search algorithm, with some optimizations
to speed up convergence:
1. Start with a guess c0. RIFRAF chooses the read with the lowest expected number
of errors.
2. For the most recent guess ci, examine a set of candidate single mutations, such
as insertions, deletions, and substitutions. Note that these candidates vary at each
optimization stage. Keep all that improve the score S(ci|R ,r). Call the set of
candidate mutations C .
3. If C is empty, accept ci and terminate. Otherwise, choose some subset of C , apply
them to ci to obtain ci+1, and iterate.
RIFRAF works in two stages, first optimizing just S(c|R ), and then optimizing
the full S(c|R ,r).
Filtering mutations
When comparing the template to the reads, we need not consider all possible
modifications to the current consensus. For example, if any candidate mutation to c does
not appear in any pairwise alignment of c with a read, that mutation need not be scored.
Since it has no support among any observed sequence, it is likely to hurt the alignment
score. Similarly, during the frame correction stage, the model only proposes insertions or
deletions that appear in the pairwise alignment to reference.
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Multiple mutations
Instead of accepting only the best mutation in C , RIFRAF accepts all the mutations
that are separated by a certain number of positions: nseparate (the default value is 15,
i.e. five codons). The candidates are accepted in order from best to worst score. This
policy allows RIFRAF to converge in many fewer iterations than if it only accepted one
mutation per iteration. nseparate ensures that the changes to the consensus are relatively
independent of each other, and that the score of one is unlikely to be affected by the
acceptance of another. After accepting mutations in C , RIFRAF also compares the new
score to the score that would be obtained from accepting only the single best mutation in
C , and optionally accepts that single mutation instead if it results in a better score.
Forward and backward alignments
Recomputing the full alignment matrix for each candidate mutation to c would be
prohibitively expensive. For a sequence c from alphabet {A,C,G,T}, there are 4(|c|+1)
insertions, 3|c| substitutions, and |c| deletions to consider. Computing the alignment
matrix A for each candidate requires O(cs) operations, so each iteration of the proposed
algorithm would require O(Nc2s) operations (we omit | · | in O(·) for clarity). Instead,
RIFRAF uses forward and backward alignments to compute the new score for any single
change to c by only recomputing a single column of A [17].
To achieve this, in addition to the prefix alignment matrix A, where ai, j is the
score for aligning prefix s1...i to prefix c1... j, RIFRAF also computes the suffix alignment
matrix B, where bi, j is the score for aligning suffix si+1...|s| to suffix c j+1...|c|. Note that
a|s|,|c| = b0,0 is the score for the full alignment. For any j, that alignment score can also
be computed from columns A·, j and B·, j:
∀ j ∈ [0 . . .v] : a|s|,|c| = b0,0 = maxi(ai, j +bi, j) (3.1)
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Modifying c j leaves unchanged columns 0 . . . j− 1 of A, and also leaves un-
changed columns j . . .v of B. Therefore, for all three types of mutations, computing the
new score requires that at most only a single new column of A must be recalculated.
1. substitution at c j: compute A·, j; new score is maxi(ai, j +bi, j).
2. insertion after c j: compute A·, j+1; new score is maxi(ai, j+1+bi, j).
3. deletion of c j: no new column necessary; new score is maxi(ai, j−1+bi, j).
Using the forward and backward alignments, all possible mutations to the con-
sensus can be scored in O(Ncs) operations.
During the alignment of the template and reference, additional columns must be
recomputed to account for codon insertion and deletion moves.
Banding
b
b||s|− |c||
Figure 3.3: Banded alignment. Alignments must stay within the banded region of the
dynamic programming matrix.
Despite the improvements from using forward and backward alignments, each
iteration is still approximately quadratic in the length of the consensus, assuming |c| ≈ |s|.
Alignment banding [15, 16] further reduces the number of operations per iteration.
For a given bandwidth parameter b, the maximum usable column size in A and B is
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2b+ ||s|− |c||  |s|, so evaluating a possible mutation requires many fewer operations
than recomputing the full column. Alignment moves are only allowed to originate inside
the band, so alignment paths must stay within the band boundaries (see Figure 3.3).
With banding, the time complexity per iteration becomes O(Nc(
√
s+b)), since ||s|− |c||
grows like
√|s| under reasonable assumptions.
RIFRAF dynamically increases the bandwidth if the number of differences in the
banded alignment is sufficiently larger than the expected number of differences implied by
the read’s quality scores, under the assumption that the difference between the template
candidate c and the true template is much smaller than the number of sequencing errors
in s. Let r be the observed number of differences between s and c, and e be the expected
number of errors computed from the quality scores p. If the value of r is in the upper
tail of a Poisson distribution with mean parameter e, then the bandwidth is doubled and
the alignments are re-computed. α controls the size of this upper tail probability, with a
default value of 0.1.
Batching
RIFRAF uses a variety of batching strategies to speed up convergence. If the
number of reads is greater than a threshold k (default 5), the best k reads by error rate are
fixed as the initial batch, and RIFRAF runs to convergence. This ensures that RIFRAF first
converges without considering the many spurious mutations presumably present in less
accurate reads. The resulting initial guess is further refined at the refinement stage, this
time with a different random batch of size nbatch (default 20) for each iteration. Sequences
are chosen for inclusion in the batch by sampling from a multinomial distribution of
their error rates, parameterized by parameter ρ between 0 and 1. When ρ = 1, all the
weight is evenly distributed among the top nbatch sequences. Interpolating from ρ= 1.0
to ρ= 0.5, the probabilities become proportional to the read error rates. Interpolating
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from ρ= 0.5 to ρ= 0, the probabilities become uniform. By default, ρ= 0.9i, where i
is the number of iterations since random batching activated. Like the fixed batch, this
strategy speeds up convergence by initially avoiding inaccurate reads, then gradually
letting them contribute to resolve uncertain bases if necessary.
Ideally, nbatch is small enough to make each iteration fast, but large enough that
RIFRAF converges stably. RIFRAF tries to detect if nbatch is too small by monitoring the
change in score after each iteration. If the new score is worse than the old score by more
than a certain percent (10% by default), nbatch is increased to 2nbatch, then 3nbatch, etc.
Combining all of the previous optimizations, a single iteration’s time complexity
is reduced from O(Nc2s) to O(nbatchc(
√
s+b).
3.2.4 Increasing indel penalties
Whenever the algorithm converges to a consensus ci, if single indel moves were
used in computing Sr(·), the single insertion and deletion scores are multiplied by a
parameter tindel , increasingly encouraging the alignment with the reference to use only
codon indels, thereby keeping c in-frame. This process repeats up to m times, so the
maximum multiplier is (tindel)m. If the penalty is large enough, the consensus will always
be forced into the reference’s reading frame, which is the default behavior. However,
some consensus sequences really are out of frame relative to the reference. The indel
penalties can be tuned so that RIFRAF correctly identifies true frameshifts, with a small
risk of allowing some spurious ones.
3.2.5 Multi-stage optimization
The full optimization procedure proceeds in stages, allowing RIFRAF to converge
quickly by focusing on different objectives in different stages.
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1. Initial stage: Do not use the reference. Propose all mutations to the consensus that
appear in the pairwise alignments. Use the fixed batch, if available. If no reference
was provided, stop after this step.
2. Frame correction stage: Use the full model, including the reference and reads.
Propose indel candidate mutations that appear in the consensus-reference alignment.
Increasingly penalize single indels in alignment of r and c. Use the fixed batch, if
available.
3. Refinement stage: Propose only substitutions (no indels) to the consensus that
appear in the pairwise alignments, no longer considering the reference. Use random
batches, with decreasing ρ.
The initial stage quickly finds a good candidate consensus from the reads alone.
The frame correction stage uses a reference to penalize indels that cause frame shift errors,
correcting the reading frame of the template in a way that is maximally compatible with
both the reads and the reference. Finally, the refinement stage ensures that the reference
influences only the frame of c, and exerts no bias upon the nucleotides themselves. The
final stage also fixes biases introduced by the fixed batch in the first two stages.
3.3 Results
We compared RIFRAF to two other methods: MAFFT [56] followed by the standard
per-column consensus, and POA [67] with the heaviest bundle consensus algorithm [66].
All three methods were run with and without reference-guided frame correction. RIFRAF
natively performs frame correction, but only if it is given a reference sequence. To
distinguish these models in this section, we refer to the model with no reference as
RIFRAFnr, and the model with a reference as RIFRAFref. FrameBot [148] was used for
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correcting results from MAFFT and POA; these are referred to as MAFFT FB and POA FB.
A full-length sequencing run of Pacific Biosciences SMRT sequencing on env
from HIV-1 subtype B strain NL4-3 was used for the comparison [63]. The true sequence
of NL4-3 is known, so results could be compared to the ground truth. The filtered
data (available on FigShare4) contains 27,600 reads with expected error rate 1% or
better, which were further filtered and processed as follows. To make the problem more
challenging and better reveal differences between methods, very high quality sequences
were excluded (expected error rate < 0.1%). Short fragments and long reads (often
concatemers) were discarded by filtering out sequences 25 bases shorter or longer than
the median of 2,597. PacBio reads come in random orientations, so reads were converted
to their reverse complement, if necessary. Extra bases around the amplicon were removed
by aligning to NL4-3 env without penalizing terminal gaps, then trimming terminal
insertions. After preprocessing, 9,473 sequences remained, with a mean error rate of
0.0015 (the distribution of errors appears in Figure S1). All experiments were run for
1,000 trials on randomly sampled reads.
Choice of reference. A set of reference sequences – shown in Figure S2 – were
tested to investigate how frame correction accuracy deteriorates for distantly-related
references. The results are shown in Figure 3.4. Nucleotide results from MAFFT FB and
POA FB were both equally insensitive to the choice of reference, whereas RIFRAFref’s
results did degrade slightly. However, the reverse is true for the protein sequences, with
RIFRAFref’s performance degrading by half an amino acid on average, and the others
degrading by more than one. This difference indicates that RIFRAFref not only keeps
the consensus in-frame, but also makes better choices of inferring which nucleotides
are truly indel errors. Finally, RIFRAFref was the most accurate, regardless of choice of
reference. As expected, RIFRAFref’s frame correction strategy works best with a closely
4https://doi.org/10.6084/m9.figshare.5643247
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related reference, but these results show that it is capable of working even with a distant
reference. Except where noted, the most distant reference, B.BR, was used for the rest of
the results.
Number of sequences. Clusters of 2, 3, 4, 5, 6, 8, 10, 15, and 20 reads were
randomly sampled for this experiment. The fraction of perfectly reconstructed consensus
sequences per 1,000 trials appears in Figure 3.5a. For fewer than ten sequences, both
versions of RIFRAF dominate the other corresponding methods. For instance, RIFRAFref
gets over 90% correct with access to only four reads. POA FB does not achieve similar
results until N = 8, and MAFFT FB does not until between N = 10 and 15. Interestingly,
POA’s results actually degrade significantly for n> 6, but POA FB continues to improve,
because POA tends to include extra bases on the ends of the consensus sequence which
are then removed by FrameBot. These extra bases also affect the average number of
nucleotide errors (Figure 3.5b): for N = 20, POA averages one error per sequence, whereas
all the other methods average none.
The average number of protein errors (Figure 3.6a) highlights the importance
of frame correction. Frame shifts cause the translated consensus sequences to differ
greatly from the true protein sequence, especially for n < 15. For N = 2, fully half of
each protein sequence is wrong on average, regardless of method. Even for N = 20,
sequences from RIFRAFnr and POA contain about 100 errors. On the other hand, the
corrected sequences (shown in Figure 3.6b for clarity) contain nearly no errors for n> 10.
RIFRAFref again performs best here, approaching zero errors even for N = 3.
Interestingly, frame correction of MAFFT and POA often made the nucleotide
sequences less accurate, whereas it improves RIFRAFref. This result supports the idea
that RIFRAF’s method of integrating frame correction into the consensus algorithm makes
it more accurate by allowing all reads to inform the correction process. FrameBot, which
only has access to a single consensus sequence, cannot use the extra information in the
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reads, and therefore cannot achieve the same accuracy.
Execution times appear in Figure 3.7. Without frame correction, all three methods
are comparable for small numbers of sequences, but RIFRAFnr scales better, due to its
batching scheme. Frame correction adds a constant factor to all three methods’ execution
times. RIFRAFref’s constant factor is larger, but, because it scales better, it overtakes the
others between N = 10 and N = 15.
Sequence length. Figure 3.7 also shows execution time for varying sequence
lengths. For more details on this experimental setup, see SI section 2. RIFRAFref scales
less well than the other methods, taking about twice as long as MAFFT FB and POA FB for
the full-length sequences. However, it is comparable with the others at `= 900, and faster
than the others for ` < 600. This difference in speed is due to RIFRAF’s iterative approach,
which requires recomputing parts of each pairwise alignment after every iteration.
Detecting true frameshifts. In the other experiments, strict frameshift penalties
were used to ensure the consensus stays in-frame. However, sometimes frameshifts are
biologically plausible, such as in integrated (but non-functional) proviral Env sequences,
or in the cytoplasmic tail of Env leading to a truncation, but preserving infectivity. If
true frameshifts may occur in the template sequence, it may be preferable to relax this
frameshift penalty. RIFRAFref can be tuned to accept frameshift indels with enough
support in the reads, with only a small increase in the frequency of spurious frameshift
indels. To demonstrate this, single base insertions and deletions were added to NL4-3 in
both homopolymer and non-homopolymer regions (details in SI section 3). tindel was set
to 1.05, and the max frameshift indel penalty multiplier m varied from 0 to 12. We call
an in-frame sequence a “positive”, so increasing m increases the false positive rate by
forcing sequences with real frameshifts incorrectly into frame. To get the true positive
rate, RIFRAFref was also run on the unmodified sequences. Note that while we introduce
only a single true indel into our “negative” cases, the analysis is always at the whole-
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sequence level. We are not just detecting the presence or absence of the specific indel
we introduce. Thus to achieve a high true positive and low false positive rate, RIFRAFref
must successfully ignore spurious indels at any position in the “positive” cases, while
successfully identifying the real indel we introduce in each “negative” case. The resulting
ROC curves, which appear in Figure 3.8 for N ∈ 3,5,10, show that RIFRAFref can find
true indels while controlling the false positive rate, using either a closely related reference
or a distant one. A useful trade-off occurs for m = 6, which scores close to the maximum
true positive rate while keeping the false positive rate close to zero.
In agreement with the accuracy results, a more closely related reference (HXB2)
improved inference for N = 3 for this task. As expected, real homopolymer indels in
homopolymer regions are harder to discriminate than non-homopolymer indels (See SI
section 3 for more detailed results).
3.4 Conclusion
RIFRAF uses quality scores and a reference sequence to infer accurate frame-
corrected consensus sequences. It can often find the correct consensus, even from small
numbers of reads or with a distant reference, as shown in our experimental results. RIFRAF
with frame correction can be slower than taking a consensus from a multiple sequence
alignment, but in experiments with real SMRT sequences it finds consensus sequences
that are significantly more accurate. The benefits of using a reference to reduce frameshift
errors are especially apparent when comparing translated amino acid sequences, where a
single frameshift causes the entire downstream sequence to be incorrect. Finally, RIFRAF
can detect and retain true frameshifts during frame correction, and, to our knowledge, is
the only method capable of this.
While RIFRAF performs well with distantly related reference sequences, perfor-
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mance is improved when using closely related references. However, when sequencing
diverse populations, we note that it is always possible to first infer a set of autologous
sequences from clusters or primer ID bundles that have a large number of reads, and so
should be accurate. These can then be used as references to correct the reading frame of
the less-represented members of the population, providing an improved accuracy over
just using a more distantly related reference. We recommend using this strategy whenever
possible.
RIFRAF can improve the ability to resolve minority variants in sequenced popula-
tions. Its ability to find results comparable to MAFFT with three times fewer reads will
be essential for identifying minority variants in the population with greater precision.
More generally, RIFRAF will be useful whenever an accurate consensus sequence must
be inferred from a small number of full-length sequences, especially when quality scores
and a reference sequence are available.
When sequencing any population, it is often advisable to sequence a clonal
representative of that population first (NL4-3 env here), to investigate the sequencing
performance for that case. We recommend using such sequence datasets to investigate the
behavior of RIFRAF on new genes, especially if the user seeks to detect real frameshifts.
To this end, we provide a Jupyter notebook that allows one to replicate the accuracy and
ROC analyses from this manuscript on any clonal amplicon dataset.
RIFRAF will continue to be developed along multiple lines. First, the current
approach for performing frame correction needs to be faster, to keep pace with the
increasing volume of available sequence data. Further work needs to be done to speed
it up via optimization or algorithmic advances. Possible approaches include: re-using
partial alignments, speeding up alignments with k-mer seeding, and only correcting the
frame of obviously problematic regions. Another improvement would include amino acid
matching penalties in the reference-to-template alignment, which would allow even more
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distantly related reference sequences to be used, where the nucleotide homology has
been completely obliterated. Another useful feature would be to infer calibrated quality
scores for the consensus sequence, in order to communicate uncertain regions to the user.
Finally, RIFRAF is extensible to other systems and sequencing technologies. In particular,
we plan to investigate its behavior and tune its error model for Oxford Nanopore data,
and to extend the method to support amplicons containing both non-coding and coding
regions, which may contain different (potentially overlapping) reading frames.
The RIFRAF source code is available at https://github.com/MurrellGroup/Rifraf.jl.
3.5 Supporting Information
3.5.1 NL4-3 and references
The distribution of estimated error rates of the NL4-3 reads appears in Figure 3.9.
The phylogenetic tree of the reference database appears in Figure 3.10.
3.5.2 Length of template experiment
As a proxy for varying amplicon lengths, we sampled prefixes of varying lengths
from our NL4-3 sequence dataset. This protocol is valid because SMRT sequencing does
not have a positional bias (see Figure S8D in [63]), so the distribution of errors in the
prefix should match the overall errors. However, these short reads are of lower overall
quality than true short CCS reads, which have the benefit of more subreads in the ZMW
read.
The experiment was run for 1,000 trials of clusters of size N = 3. The fraction of
correct consensus sequences appears in Figure 3.11a. Although all methods degrade in
accuracy for longer sequences, RIFRAFref degrades much more slowly, getting at least
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80% perfectly correct even for the full-length amplicon. For this number of sequences,
RIFRAFref beats even the other methods with frame correction. As expected, frame
correction keeps all three methods in-frame (Figure 3.12a). The amino acid edit distance
for frame correction methods alone appears in Figure 3.12b for clarity, showing that
RIFRAFref’s frame-corrected amino acid sequences contain an average of less than one
error even for the full-length amplicon, whereas the accuracy of other methods degrades
from one error all the way to three errors for POA FB and four errors for MAFFT FB.
3.5.3 True indel experiments
Single indels were simulated in both homopolymer (defined as four or more
identical bases in a row) and non-homopolymer regions of NL4-3 in the following manner.
First, a region was sampled uniformly from all matching regions; i.e. a homopolymer
region is chosen at random from all homopolymer regions. Insertions or deletions in
homopolymer regions were simulated by inserting or deleting a base. Deletions to non-
homopolymer regions were simulated by removing a single random base from that region.
Insertions in non-homopolymer regions were simulated by choosing a non-homopolymer
position and inserting a random base either before or after it.
Each read has a small probability p of not being modified to match the new
template, where p is proportional to the read’s estimated error rate and is calculated as
the mean of the Phred scores after converting them to error probabilities. Those reads
that were modified were pairwise aligned to the template and the matching base was
inserted or deleted from the correct position. Quality scores for insertions were drawn
from a uniform distribution between the two Phred scores on either side of the insertion.
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(a) DNA sequence edit distance for increasingly distant references.
NL4-3 HXB2 B.DK B.ES B.CN B.BR
reference
0
1
2
3
4
5
pr
ot
ei
n 
ed
it 
di
st
an
ce
RIFRAF_ref
MAFFT_FB
POA_FB
(b) Protein sequence edit distance for increasingly distant references.
Figure 3.4: Edit distance for increasingly distant references. All methods do better
with closely-related reference, but their rate of performance degradation is important
because a related reference may not always be available. Run with N = 3 full-length
reads.
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(a) Fraction of correct sequences versus number of sequences.
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(b) DNA edit distance versus number of sequences.
Figure 3.5: DNA results. Fraction of correct sequences (left) and mean edit distance
between the consensus and the template (right) for increasing N.
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(a) Protein edit distance versus number of sequences; all methods.
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(b) Protein edit distance versus number of sequences; frame correction only
Figure 3.6: Same results as Fig. 3.5, but for the translated protein sequences. The
fraction of correct sequences is not reproduced, since those figures are identical. The
left figure show results for all methods. The right figure show the same data, zoomed to
show the frame-corrected results. Note Y axis scale.
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300 600 900 1200 1800 2100 2565
template length
0
2
4
6
8
10
12
14
ru
nn
in
g 
tim
e 
(s
ec
on
ds
)
RIFRAF_ref
RIFRAF_nr
POA_FB
POA
MAFFT_FB
MAFFT
(b) Mean execution time versus template length.
Figure 3.7: Mean execution time, varying both number of sequences (left) and
sequence length (right). Note that intervals on the x-axis are not linear.
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Figure 3.8: ROC curves for true indel experiments, with max indel penalty multiplier
m varying from 0 to 12. The orange point denotes results from RIFRAFnr, while the
remainder of the curve was generated by RIFRAFref. The green point corresponds to a
max indel penalty multiplier m = 6. Both a related reference (HXB2, blue) and distant
reference (B.BR, red) were used.
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Figure 3.9: QV-derived error rates of the NL4-3 sequences used.
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Figure 3.10: Phylogeny of references used by RIFRAFref. The references were aligned
with MAFFT [56, 57], the phylogeny inferred by FastTree [109, 110], and visualized
with PhyloTree.js (https://github.com/veg/phylotree.js).
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(a) Fraction of correct sequences versus template length.
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(b) DNA edit distance versus template length.
Figure 3.11: Results on DNA sequences for varying sequence length. The left figure
shows the fraction of correct sequences; the right figure shows mean edit distance
between the consensus and the template.
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(a) Protein edit distance versus template length; all methods.
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Figure 3.12: Same results as Fig. 3.11, but for the translated protein sequences. The
fraction of correct sequences is not reproduced, since those figures are identical. The
left figure show results for all methods. The right figure shows the same data, zoomed
in on the details of the frame-corrected results.
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Figure 3.13: ROC curves for true indel experiments, with max indel penalty multiplier
m from 0 to 12. Orange points denote runs without a reference; the rest use HXB2 as a
reference. The green point corresponds to a max indel penalty multiplier m = 6.
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Figure 3.14: The same results as in Figure 3.13, except using the more distant
sequence B.BR as a reference.
Chapter 4
Biological applications
4.1 Introduction
The FLEA pipeline has already been used in multiple papers to provide new
biological insights into the evolution of HIV-1. It has been used to characterize the
mutations in env that potentially drive the development of lineages of broadly neutralizing
antibodies in the Protocol C cohort. It has also been used to study evolution and escape
during a phase I clinical trial of monoclonal antibody 10-1074.
4.2 Protocol C
The Protocol C cohort is a group of 439 HIV-positive subjects from multiple
regions in sub-Saharan Africa that participated in a multi-year longitudinal study to
investigate the factors leading to the development of broadly neutralizing antibodies
[64]. HIV-negative individuals were monitored and enrolled in the study after they
contracted HIV, ensuring that data collection started as soon as possible after the initial
infection event. Blood draws were taken at regular intervals and neutralization assays
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were performed against a panel of heterologous virus. Consistent with other estimates
of bNAb frequency, 15% of participants developed bNAbs, most after two to four years
of infection. A summary of their neutralization scores over time appears in Figure 4.1.
Another third of the participants developed some neutralization breadth, but not enough
to be characterized as broad. Among those that did develop bNAbs, 40% of them targeted
the N332 glycan supersite in V3.
This study emphasized the need to perform in-depth followup studies in order to
understand how to elicit bNAbs:
A detailed analysis of the development of bNAb lineages in top neutralizers
will help understand which specificities are most amenable to elicitation
through vaccination and whether Env evolution pathways associated with
specific lineages suggest particular immunogen designs or vaccine strategies.
([64])
Those in-depth analyses are currently underway. Of the top forty-six donors,
PC039, PC064, and PC076 (marked in Figure 4.1) have already been studied with a
combination of strategies such as neutralization assays, longitudinal sequencing of both
the B-cell lineage and the Env population, structure determination of antibodies, and
some Env/Ab complexes. In all three cases, FLEA was used to analyze the longitudinal
Env sequences. This section highlights the major biological insights from each of those
donors, with an emphasis on the contributions of FLEA to the results.
4.2.1 PC039
Donor PC039 developed antibody lineages targeting the N332 glycan supersite
in variable loop 3 (V3), which was the most common target observed in the Protocol
C cohort. The donor developed a maximum neutralization score of 2.0 at 60 months
post infection. This donor is also notable because they were infected with two founder
variants, which recombined and then evolved into two stable sub-populations, each
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Figure 4.1: Best neutralizers from the Protocol C cohort. The 46 best neutralizers had
neutralization score ≥ 1. Neutralization score shown for each month. NT: Not Tested.
ART: on ART during visit. OFF: off-study during this visit. The three donors for which
FLEA was used during followup studies (PC039, PC064, PC076) are marked. Image
adapted from Figure 1C [64].
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Figure 4.2: Histogram of amino acid frequencies in PC039 for each time point. Only
differences from one of the parent MRCA sequences are shown. The other parent is
clearly visible at 3MPI. From Figure 1 [95].
Figure 4.3: PNGS locations in PC039. Fraction of PNGS sites at each position. From
Figure 2 [95].
of which separately escaped the antibody lineage. The early presence of at least two
founders, followed by recombination, may possibly have contributed to the antibody
lineage development.
The full-length env sequencing protocol was used to sequence the population at
twelve time points, from three to sixty months post infection. FLEA was used to generate
HQCSs, align them, and perform phylogentic analyses. Per-site amino acid frequences
(Figure 4.2) clearly show the presence of both founder variants at 3 MPI, which also
appear in the phylogenetic tree in Figure 4.5.
These multiple founders, plus the high recombination rate in HIV-1, means that
alignment columns do not share a common ancestry, which is an assumption of most
phylogenetic analyses. Therefore, the inferred tree does not capture the true within-host
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Figure 4.4: Inferred recombination in PC039. Posterior probability that each base
came from parent A (blue) or parent B (red). Little recombination is visible at 3 MPI.
Sequences become increasingly recombined over time. Black regions denote gaps in
the alignment. From Figure 3 [95].
evolutionary history of the virus [122, 125]. To better understand these lineages, we also
visualized the population in a different way by using Multidimensional Scaling (MDS)
[60] to embed the sequences in two-dimensional space while preserving the pairwise
distances. The embedding clearly shows the branching and independent evolution of
two sub-populations of Env (Figure 4.6). A stable mixture of two sub-populations of
recombinants appeared by 17 MPI, which had already escaped. Subsequently each
population proceeded along different evolutionary pathways. This data was inspiration
for the MDS visualization in FLEA, as shown in Figure 2.4.
A previously-described recombination model [80] was implemented and cus-
tomized to infer the amount of recombination in each HQCS. The two founder variants
were inferred from the earliest time point and used to build a hidden Markov model
(Figure 4.7), keeping only the positions that differed in at least one parent. The model
was intilized with constant transition and emission matrices, then trained using Viterbi
training [114] with the constraint that the transition matrix must be symmetric with a
constant diagonal. The forward and backward algorithms were used to compute the
posterior probability that each base came from each parent. The training and inference
process was repeated independently for each sequence. A visualization of the posterior
81
Figure 4.5: Phylogenetic tree of Env in PC039, with nodes colored according to time
point. The diverging ladder structure is due to recombination and diverging
sub-populations. Marked IC50 values show escape at later time points. From Figure
4A [95].
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Figure 4.6: MDS embedding of Env in PC039. Multidimensional scaling (MDS) was
used to generate a low-dimensional embedding of Env HQCSs sequences that preserves
pairwise distances. Node color shows time since infection, and node size is
proportional to inferred abundance. The evolution of two independent populations of
Env is clearly visible. The populations derived from the two founder sequences are
clearly visible (orange). They recombine, then split into separate lineages around 23
MPI. From Figure 4C [95].
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Figure 4.7: HMM for inferring recombination of two parent sequences to generate an
observed child sequence. Each column in their alignment corresponds to a state from
each parent. Transitioning to the other parent models a recombination event. The
shown probabilities are meant to be representative, as the true probabilities differ for
each observed sequence after Viterbi training.
probabilities for all HQCSs is shown in Figure 4.4.
The two Env lineages contained many genetic differences, such as the 322-323
motif, as shown in Figure 4.9, the 324-327 motif, as shown in Figure 4.8, the location
of glycans (Figures 4.10 and 4.3) and the composition of the V1 loop. In particular, the
deletion observed at position 322 has been functionally validated by mutagenesis and
neutralization assay, and explains escape from the PC039 antibody lineage for the top
arm of the MDS plot.
This work was presented by Ben Murrell in 2016 at Keystone [95]. Further work
is ongoing.
4.2.2 PC076
Donor PC076, who was infected by HIV-1 subtype C, also developed a bNAb
lineage targeting the N332 region, here referred to as the high-mannose patch. This
donor’s lineage is notable because at least one of its antibodies achieved breadth without
a large number of complex changes: it had a small number of somatic hypermutations
and no insertions or deletions. This result has implications for vaccine design, because it
should be faster and easier to induce such an antibody, compared to one that requires an
older, more complicated lineage. Presumably, the longer it took during natural infection
84
Figure 4.8: [MDS embedding showing positions 332 and 333 in PC039. From an
ongoing collaboration.
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Figure 4.9: MDS embedding showing positions 324-327 “GDIR” motif in PC039.
From an ongoing collaboration.
Figure 4.10: Glycan dynamics in PC039, and corresponding development of breadth.
Both lineages had almost entirely escaped by 17 MPI. From [95].
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for a bNAb to develop, the more rounds of sequential vaccination would be required, if it
is possible at all.
The investigation proceeded as follows:
• Confirm a broadly neutralizing response and find its target on Env. Neutralization
assays detected a broad neutralizing response at 33 MPI and N332 activity. They
further confirmed that the response is N332 dependent by checking that a point
mutation which eliminates the glycan (N332A) is a neutralization knockout.
• Find the responsible mAbs. Twelve potent monoclonal antibodies (mAbs) were
isolated from the blood samples and sequenced via single-cell sequencing. Individ-
ual antibodies were tested against the neutralization panel of pseudoviruses, and
the three most potent were further investigated on another panel.
• Study Env population to find the variants that triggered the Ab lineage, mutations
that drove the lineage evolution, and eventual escape mutations. 76 autologous
full-length env sequences were cloned and sequenced via Sanger sequencing. The
capacity of each of the 12 mAbs (from the previous step) to neutralize these
suggested that the lineage was triggered by virus that emerged between 5 and 10
months. The Env sequences from those time points were checked for common
mutations. Mutations were confirmed by introducing them to the most common
virus and again checking for neutralization.
• Track mAb lineages that lead to the potent mAbs. Deep sequencing was used to
track the mAb lineages leading to the bNAbs studied in step #2. Multiple early
lineage arms developed in parallel.
• Get Fab structure. In order to better understand binding and possible mechanism
of neutralization, the structure of the Fab was resolved.
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An early version of FLEA was used to align and analyze the Env sequences.
Because sequences came from Sanger sequencing, not SMRT sequencing, the quality and
consensus sub-pipelines were not necessary. Instead, the Sanger sequences were treated
like HQCSs and fed directly into the alignment and analysis sub-pipelines. The results of
those analyses helped to identify residues in Env that contributed to the evolution of the
lineage. Those mutations could then be verified via mutagenesis.
This work was published in [75].
4.2.3 PC064
Donor PC064, who was infected by HIV-1 subtype A, developed a bNAb lin-
eage targeting the V2 apex epitope. Fewer donors in the Protocol C cohort developed
antibodies targeting V2, which is consistent with the estimated rate of 10-25% among
those that do develop bNAbs [49]. Like the lineage from PC076, this lineage contained a
low amount of somatic hypermutation and no indels, making it a realistic candidate for a
vaccine.
Full-length longitudinal SMRT sequencing of env was performed, and the results
were analyzed with FLEA. The inferred tree appears in Figure 4.11.
The HQCSs reconstructed by FLEA revealed key insights into the evolution of Env
that could lead to a method to elicit V2-targeting antibody lineages. They showed the V2
variants that drove the development of breadth and the eventual escape trajectory, which
occurred via mutations at positions 166, 167 and 169. The pattern of these mutations
over time suggests that the mAb lineage evolved towards greater breadth as a response
to successive escape mutations at these positions. The HQCSs also show that the Env
population continued to evolve after full escape. These further changes are possibly
restoring fitness lost during the escape.
This work was published in [65].
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Figure 4.11: Phylogenetic tree of Env in PC064. Node size is proportional to
abundances, and colors correspond to time point. Dotted lines show location of Sanger
sequences, which agree with the HQCSs inferred from the SMRT sequencing reads.
From Figure 4[63].
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4.3 Phase I clinical trial of antibody 10-1074
FLEA was also used as part of a recent study describing a phase I clinical trial of a
broadly-neutralizing monoclonal antibody [14]. As an alternative to eliciting antibodies
through vaccination, another approach is to manufacture monoclonal antibodies originally
isolated from donor studies (such as those described above), and directly inject them as
an antibody therapy. They confer the same neutralization benefits, both in preventing
infection and in controlling viremia during infection, so this approach is being considered
as an alternative or supplement to both vaccines and ART. Unlike native antibodies,
however, passively introduced antibodies get depleted and would have to be replenished.
This antibody used in this clinical trial, 10-1074, was isolated from an African
donor described in [90]. Like the lineage in PC076 [75], this antibody also targets the V3
epitope centered on N332. 10-1074 is one of the more potent and broad monoclonal anti-
bodies found so far. It neutralized 60.5% of pseudovirus in a large panel of neutralization
assays and 77.7% of isolates from HIV-1 infected individuals from the US and Germany.
In this study, 33 individuals (14 uninfected, 16 infected and off ART, 3 infected and on
ART) received a single dose of varying concentration to assess its medical safety and its
efficacy as a therapy for controlling viremia.
The therapy did successfully reduce viremia for a short time (approximately ten
days) before the viral population evolved escape mutations and viremia rebounded. A
variety of sequencing protocols were used to study this escape. Single genome sequencing
(SGS) was used to sequence Env before and after treatment. It confirmed sensitivity to
antibody before treatment and showed that most sequences escaped via N332 or S334
mutations that removed a PNGS. However, its depth was too low to look for minority
variants: a total of 1,111 Env sequences were acquired for 15 subjects, for an average of
37 sequences per subject per time point. Primer ID based deep sequencing (PIDS) of
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Figure 4.12: Escape in donor 1HD1. Multiple loss of glycan mutations appeared by
week four, then 325K took over by week sixteen. This suggests that the final escape
mutant was present at low frequencies and took longer to take over the population.
Unpublished data from ongoing work with Ben Murrell.
the V3 region was also done for fifteen subjects, which could identify minority variants,
since it was powered to detect mutations at 1.0% frequency, with a range of 0.5% to
2.4%). However, by focusing on only the V3 region, PIDS missed the other changes
occurring in the rest of env. Finally, full-length SMRT sequencing of env in three subjects
was performed, and analyzed with FLEA. Note that the amino acid frequencies inferred by
FLEA agreed with the SGS and PIDS frequencies, which independently confirms FLEA’s
accuracy.
The phylogenies inferred by FLEA showed that two of the three subjects already
had Env populations with multiple escape variants at low frequencies prior to initiation
of therapy. The results also showed that all three viral populations had escaped by the
fourth week of the trial via mutations at the same few positions in V3: positions 324-327
(the ”GDIR” motif) and the PNGS at 332-334. New, unpublished longitudinal data from
donor 1HD1 appears in Figure 4.12.
The aligned full-length sequences from FLEA also suggested that the escaped
variants were still vulnerable to bNAbs targeting other epitopes. This vulnerability
provides support for the idea that, like HAART, vaccines and monoclonal antibody
therapies will need to prevent escape by targeting multiple Env epitopes simultaneously.
This work was published in [14].
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Chapter 5
Conclusion
During my doctoral program I developed new tools and algorithms to investigate
the evolution of diverse populations of HIV-1 env using longitudinal SMRT sequencing.
The first is FLEA, a pipeline for aligning, analyzing, and visualizing Env sequences. FLEA
has already been used to study donors that developed broadly-neutralizing antibodies
and to study the effects of a monoclonal antibody in a phase 1 clinical trial. The second
is RIFRAF, a consensus algorithm that takes advantage of quality scores and that keeps
the consensus sequence in frame. In addition to these projects, I also contributed to
BUSTED, a new method for identifying episodic positive selection [94]
Both FLEA and RIFRAF are undergoing active development. The process of
integrating RIFRAF into the pipeline and using the modified pipeline for new projects is
currently underway. Just like RIFRAF made FLEA more accurate by replacing an off-the-
shelf consensus algorithm for consensus sequences with one designed specifically for
the problem at hand, improvements for other parts of the pipeline, such as clustering,
are currently being developed. Moreover, although it has only been used for HIV-1
Env, FLEA is being adapted to other proteins in HIV-1 and even to amplicons from other
pathogens. Its reference databases, error models, and parameters would need to be
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updated appropriately,
One outstanding question for FLEA, and more generally for the analysis of any
recombining virus, is how to deal with such recombination. HIV-1 recombines at a
high rate, which adds an extra layer of difficulty to the problem of reconstructing its
evolutionary history and invalidates the assumptions underpinning methods such as
phylogeny reconstruction. Methods exist for identifying recombination [11, 79], but
currently there are no good ways to accurately reconstruct phylogenies of recombinant
sequences. We plan to first address this issue by inferring recombination in every time
point using the HMM model mentioned in the previous chapter and visualizing the
results.
Finally, FLEA is being used to analyze breakthrough infections in two vaccination
studies, involving SIV and SHIV (SIV with an HIV Env) challenge of immunized
macaques. Preliminary data from the SIV challenge suggest a sieve effect, where low-
frequency pre-existing escape mutants are crossing the transmission barrier and seeding
the infection. This shows that FLEA is useful not just to study primary infection, but also
for translational vaccine research.
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